



4Q & FY 2020

Financial Results

BAUSCH Health

Forward-Looking Statements



This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding Bausch Health's future prospects and performance (including the Company's 2021 full-year guidance and targeted three-year CAGR¹ of revenue growth and Adjusted EBITDA (non-GAAP) growth), expectations for cash generated from operations and the anticipated uses of same, expectations regarding gross margin, the Company's plan to spin off or separate its eye health business from the remainder of Bausch Health, including the timing of the internal organizational design/structure and capitalization structure of such transaction, the anticipated dis-synergies resulting from such transaction (including the allocation thereof between the separated entity and the remainder of Bausch Health) and the targeted leverage of the separated entity and the remainder of Bausch Health, the anticipated impact of the COVID-19 pandemic on the Company and its financial condition, results of operation, revenues, segments, liquidity, products and product pipeline, operations, facilities, supply chain and employees, planned efforts to address the COVID-19 pandemic, the anticipated timing, speed and magnitude of the Company's recovery from the COVID-19 pandemic (including expectations by geography and business unit), expected durability of certain of our products and brands, the anticipated submission, approval and launch dates for certain of our pipeline products and R&D programs, the anticipated timing of commencement and resumption of studies or other development work of our pipeline products and R&D programs, the anticipated timing of the loss of exclusivity of certain of our products and the expected impact of such loss of exclusivity on our financial condition, the Company's core priorities to drive return to growth, the Company's strategic focus for 2021 and beyond, management's commitments and expected targets and our ability to achieve the action plan and expected targets in the periods anticipated, and the Company's plans and expectations for 2021 and beyond. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "predicts," "goals," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," "commit," "forecast," "tracking," or "continue" and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's 2021 full-year guidance and targeted three-year CAGR of revenue growth and Adjusted EBITDA (non-GAAP) growth, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19, and the potential effects of that pandemic, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease). They also include, but are not limited to, risk and uncertainties caused by shareholder activism by our existing or future investors, including the distraction of our management and employees caused by such shareholder activism, the time, resources and costs expended in connection with such shareholder activism and the impact of such shareholder activism on our business plans and strategies and our ability to effectively implement such plans and strategies. They also include, but are not limited to, risks and uncertainties relating to the Company's proposed plan to spin off or otherwise separate its eye health business from the remainder of Bausch Health, including the expected benefits and costs of such transaction, the expected timing of completion of such transaction and its terms, the Company's ability to complete such transaction considering the various conditions to the completion of such transaction (some of which are outside the Company's control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other

conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following transaction, diversion of management time on transaction-related issues, retention of existing management team members, the reaction of customers and other parties to such transaction, the qualification of such transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from either or both of the Canada Revenue Agency and the Internal Revenue Service will be sought or obtained), potential dissynergy costs between the spun off or separated entity and the remainder of Bausch Health, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets Bausch Health is engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting Bausch Health's business. In particular, the Company can offer no assurance that any spinoff or other separation transaction will occur at all, or that any such transaction will occur on the terms and timelines anticipated by the Company. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, assumptions regarding our 2021 full-year guidance with respect to expectations regarding base performance and management's belief regarding the impact of the COVID-19 pandemic and associated responses on such base performance and the operations and financial results of the Company generally, expected currency impact, the expected timing and impact of loss of exclusivity for certain of our products, adjusted SG&A expense (non-GAAP) and the Company's ability to continue to manage such expense in the manner anticipated, the anticipated timing and extent of the Company's R&D expense, and expectations regarding gross margin; assumptions respecting our targeted three-year CAGR of revenue growth and Adjusted EBITDA (non-GAAP) growth including, without limitation, management's belief regarding the impact of the COVID-19 pandemic and associated responses on the operations and financial results of the Company, constant currency and from mid-point of Feb. 2019 guidance (adjusted for current exchange rates); and assumptions that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Additional information regarding certain of these material factors and assumptions may also be found in the Company's filings described above. Management has also made certain assumptions in assessing the anticipated impacts of the COVID-19 pandemic on the Company and its results of operations and financial conditions, including: that there will be no material restrictions on access to health care products and services resulting from a possible resurgence of the virus on a global basis in 2021; there will be increased availability of effective vaccine; that strict social restrictions seen in the first half of 2020 will not be materially reenacted in the event of a material resurgence of the virus; that there will be an ongoing gradual global recovery as the macroeconomic and health care impacts of the COVID-19 pandemic run their course; that the largest impact to the Company's businesses were seen in the second quarter of 2020; anticipate that our affected businesses could possibly return to pre-pandemic levels during 2021, but that rates of recovery will vary by geography and business unit, with some regions and business units expected to lag in recovery possibly beyond 2021 and no major interruptions in the Company's supply chain and distribution channels. If any of these assumptions regarding the impacts of the COVID-19 pandemic are incorrect, our actual results could differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given, February 24, 2021, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.

Distribution or reference of this deck following February 24, 2021 does not constitute the Company re-affirming guidance.

Non-GAAP Information



To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures including (i) Adjusted EBITDA, (ii) Adjusted EBITA, (iii) EBITA Margin, (iv) Adjusted Gross Profit/Adjusted Gross Margin (v) Adjusted Selling, A&P, (vi) Adjusted G&A, (viii) Adjusted SG&A, (ix) Total Adjusted Operating Expense, (x) Adjusted Net Income, (xi) Adjusted Tax Rate, (xii) Organic Revenue, Organic Growth, Organic Change and Organic Revenue Decline, (xiii) Constant Currency and (xiv) Adjusted Cash Flows from Operations. Management uses some of these non-GAAP measures as key metrics in the evaluation of Company performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are shown in the appendix hereto. However, for guidance and expected CAGR¹ purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP net income (loss) and projected Adjusted Cash Generated from Operations (non-GAAP) to projected GAAP Cash Flows from Operating Activities, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. In periods where significant acquisitions or divestitures are not expected, the Company believes it might have a basis for forecasting the GAAP equivalent for certain costs, such as amortization, that would otherwise be treated as a non-GAAP adjustment to calculate projected GAAP net income (loss). However, because other deductions (e.g., restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) may vary significantly based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amounts of these deductions may be material and, therefore, could result in GAAP net income (loss) being materially different from (including materially less than) projected Adjusted EBITDA (non-GAAP).



Today's Topics

1

2020 Highlights & Financial Results

2

FY 2021 Guidance

3

Segment Results & Recovery

4

Driving Growth in 2021 & Beyond

5

Spinoff Update

2020 Highlights & Financial Results

Exiting 2020 with Solid Momentum...



Strong Execution

- Outperformed high end of latest guidance by generating revenue for 2020 that exceeded \$8.0B
- Delivered strong adjusted EBITDA (non-GAAP)² for 2020 at top end of guidance range
- Produced solid cash from operations for 2020 that exceeded \$1.1B
- Remained focused on deleveraging; repaid debt by ~\$900M in 2020



Implemented COVID-19 Recovery Plan

- Displayed strong recovery trends across all business segments
- Grew market share across key promoted brands
- Invested behind pipeline for future growth opportunities

...Well Positioned for 2021¹



Executing Our Business Recovery from COVID-19

- Positioned to benefit from tailwinds from the recovery



Unleashing Growth Drivers

- Capitalize on key growth drivers and catalysts
- Grow EBITDA, improve working capital and delever
- Continue to invest behind strong, durable brands and strengthen the pipeline



Accelerating Strategic Alternatives to Drive Shareholder Value

- Excluding divestitures, targeting ~\$1B of debt paydown in 2021
- All internal objectives necessary for the spin of Bausch + Lomb anticipated to be achieved by 3Q21

Bausch Health 2020 Update: Recovery In Progress

BAUSCH+Health

4Q20 Organic Revenue Decline^{1,2}: **(1%)**

4Q20 Reported Revenue: **0%**

FY20 Organic Revenue Decline^{1,2}: **(6%)**

FY20 Reported Revenue Decline: **(7%)**

BAUSCH+LOMB

- Organic revenue decline^{1,2} of (6%) vs. FY19 and flat vs. 4Q19
- Global Vision Care saw growth in U.S. during FY20 but declined ex-U.S., mainly driven by Asia Pacific
- Global Consumer saw strength from eye vitamin franchise (Ocuvite® + PreserVision®) and LUMIFY® during FY20
- International Rx saw organic revenue growth^{1,2} during FY20, driven by demand in Mexico and Egypt
- Launched SiHy daily as INFUSE® in U.S. and ULTRA® ONE DAY in Australia, Hong Kong and Canada

Salix
PHARMACEUTICALS

- Reported revenue decline of (6%) vs. FY19 and 2% growth vs. 4Q19
 - \$109M LOE⁴ drag for FY20, mainly due to APRISO® LOE⁴
- XIFAXAN® reported revenue growth of 2% vs. FY19 and 4% vs. 4Q19; hit record high quarterly revenue, reporting \$411M in 4Q20
- TRULANCE® reported revenue growth of 49% vs. FY19 with 47% TRx growth vs. FY19³
- RELISTOR® reported revenue growth of 4% vs. FY19 with 9% TRx growth vs. FY19³

Ortho | Dermatologics

- Organic revenue decline^{1,2} of (3%) vs. FY19 and (1%) vs. 4Q19
 - \$37M LOE drag for FY20, mainly due to ELIDEL® and ZOVIRAX® LOE⁴
- Thermage® reported revenue growth of 47% vs. FY19 and 46% vs. 4Q19; driven by China as well as expansion into new geographies
- JUBLIA® saw reported revenue growth of 3% compared to FY19

Diversified Products

- Organic revenue decline^{1,2} of (9%) vs. FY19 and (9%) vs. 4Q19
- WELLBUTRIN®/APLENZIN® combined reported revenue growth of 13% vs. FY19

Additional Highlights

- **\$1,111M of cash generated from operations (GAAP) during FY20**
- **Repaid ~\$900M of debt in 2020 using cash generated from operations and more efficient cash management**
- No debt maturities or mandatory amortization payments until 2024
- ~\$740M revenue impact from COVID during FY20

1. See Slide 2 and Appendix for further non-GAAP information.

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. IQVIA NPA monthly.

4. Loss of exclusivity.

4Q20 and FY20 Revenue Results

	Three Months Ended		Favorable (Unfavorable)		Twelve Months Ended		Favorable (Unfavorable)	
	12.31.20	12.31.19	Reported	Organic Change ^{1,2}	12.31.20	12.31.19	Reported	Organic Change ^{1,2}
Bausch + Lomb/International	\$1,242M	\$1,238M	0%	0%	\$4,408M	\$4,739M	(7%)	(6%)
Global Vision Care Revenue	\$213M	\$210M	1%	(1%)	\$755M	\$848M	(11%)	(11%)
Global Surgical Revenue	\$182M	\$193M	(6%)	(7%)	\$576M	\$698M	(17%)	(17%)
Global Consumer Revenue	\$386M	\$390M	(1%)	(1%)	\$1,434M	\$1,455M	(1%)	0%
Global Ophtho Rx Revenue	\$139M	\$155M	(10%)	(10%)	\$504M	\$638M	(21%)	(20%)
International Rx Revenue	\$322M	\$290M	11%	12%	\$1,139M	\$1,100M	4%	6%
Salix	\$527M	\$517M	2%	2%	\$1,904M	\$2,022M	(6%)	(6%)
Ortho Dermatologics	\$160M	\$158M	1%	(1%)	\$553M	\$565M	(2%)	(3%)
Ortho Dermatologics	\$73M	\$94M	(22%)	(22%)	\$300M	\$371M	(19%)	(19%)
Global Solta	\$87M	\$64M	36%	31%	\$253M	\$194M	30%	29%
Diversified Products	\$284M	\$311M	(9%)	(9%)	\$1,162M	\$1,275M	(9%)	(9%)
Neuro & Other Revenue	\$160M	\$168M	(5%)	(5%)	\$674M	\$715M	(6%)	(6%)
Generics Revenue	\$99M	\$117M	(15%)	(15%)	\$415M	\$459M	(10%)	(10%)
Dentistry Revenue	\$25M	\$26M	(4%)	(4%)	\$73M	\$101M	(28%)	(28%)
Total Company	\$2,213M	\$2,224M	0%	(1%)	\$8,027M	\$8,601M	(7%)	(6%)

4Q 20

Financial Results

	Three Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Revenues	\$2,213M	\$2,224M	0%	(1%)	(1%)
GAAP Net Loss	(\$153M)	(\$1,516M)			
Adj. Net Income (non-GAAP) ¹ <i>Diluted Shares Outstanding⁵</i>	\$478M <i>359.0M</i>	\$404M <i>359.2M</i>	18%	18%	
GAAP EPS	(\$0.43)	(\$4.30)			
GAAP CF from Operations	\$394M	\$234M	68%		
<i>Adj. Cash Flows from Operations (non-GAAP)¹</i>	<i>\$475M⁶</i>	<i>\$234M</i>	<i>103%</i>		
Gross Profit ⁴ (excluding amortization and impairments of intangible assets)	\$1,568M	\$1,589M	(1%)	(2%)	
Gross Margin	70.9%	71.4%	(50 bps)		
Selling, A&P	\$448M	\$483M	7%	8%	
Adj. G&A (non-GAAP) ¹	\$155M	\$163M	5%	4%	
R&D	\$119M	\$114M	(4%)	(4%)	
Total Adj. Operating Expense (non-GAAP) ¹	\$722M	\$760M	5%	6%	
Adj. EBITA (non-GAAP) ¹	\$846M	\$829M	2%	3%	
Adj. EBITDA (non-GAAP) ¹	\$911M	\$898M	1%	2%	

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See Appendix for details on amortization and impairments of intangible assets.

5. This figure includes the dilutive impact of options and restricted stock units of approximately 3,182,000 and 6,658,000 and common shares for the three months ended December 31, 2020 and 2019 which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in this calculation would have been anti-dilutive.

6. Excludes net legacy legal settlements (\$79M), separation payments and separation-related payments (\$2M).

FY 20

Financial Results

	Twelve Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Revenues	\$8,027M	\$8,601M	(7%)	(6%)	(6%)
GAAP Net Loss	(\$560M)	(\$1,788M)			
Adj. Net Income (non-GAAP) ¹ <i>Diluted Shares Outstanding⁵</i>	\$1,428M <i>358.2M</i>	\$1,559M <i>357.2M</i>	(8%)	(5%)	
GAAP EPS	(\$1.58)	(\$5.08)			
GAAP CF from Operations	\$1,111M	\$1,501M	(26%)		
<i>Adj. Cash Flows from Operations (non-GAAP)¹</i>	<i>\$1,235M⁷</i>	<i>\$1,501M</i>	<i>(18%)</i>		
Adj. Gross Profit (non-GAAP) ^{1,4,6} (excluding amortization and impairments of intangible assets)	\$5,778M	\$6,256M	(8%)	(7%)	
Adj. Gross Margin (non-GAAP) ^{1,6}	72.0%	72.7%	(70 bps)		
Selling, A&P	\$1,707M	\$1,913M	11%	10%	
Adj. G&A (non-GAAP) ¹	\$579M	\$584M	1%	2%	
R&D	\$452M	\$471M	4%	4%	
Total Adj. Operating Expense (non-GAAP) ¹	\$2,738M	\$2,968M	8%	8%	
Adj. EBITA (non-GAAP) ¹	\$3,040M	\$3,288M	(8%)	(7%)	
Adj. EBITDA (non-GAAP) ¹	\$3,294M	\$3,571M	(8%)	(6%)	

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See Appendix for details on amortization and impairments of intangible assets.

5. This figure includes the dilutive impact of options and restricted stock units of approximately 3,154,000 and 5,106,000 common shares for the twelve months ended December 31, 2020 and 2019, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in those calculations would have been anti-dilutive.

6. 2020 numbers are on an as reported basis, no adjustments reflected in 2020.

7. Excludes net legacy legal settlements (\$122M), separation payments and separation-related payments (\$2M).

FY 20

Cash Flow Summary

	Three Months Ended 12.31.20	Three Months Ended 12.31.19	Twelve Months Ended 12.31.20	Twelve Months Ended 12.31.19
Net loss ¹	(\$152M)	(\$1,517M)	(\$559M)	(\$1,783M)
Net cash provided by operating activities	\$394M	\$234M	\$1,111M	\$1,501M
Net cash used in investing activities	(\$84M)	(\$85M)	(\$261M)	(\$419M)
Net cash (used in) provided by financing activities ³	(\$503M)	\$2,255M ⁶	(\$2,294M) ²	\$1,443M ⁶
Net (decrease) increase in cash, cash equivalents and restricted cash ³	(\$172M)	\$2,417M ⁶	(\$1,428M) ²	\$2,521M ⁶
Cash, cash equivalents and restricted cash at end of period	\$1,816M ⁴	\$3,244M ⁶	\$1,816M ⁴	\$3,244M ⁶

\$1,111M of cash generated from operations (GAAP) during FY20; **\$1,235M⁵** adjusted cash flows from operations (non-GAAP)⁷

Cash from operations negatively impacted by COVID-19 vs. prior year

Adj. cash generated from operations (non-GAAP)⁷ for 2021 is expected to be ~\$1.5B^{8,9}

1. Net loss before net loss (income) attributable to noncontrolling interest.

2. Includes \$1,240M redemption of 5.875% May 2023 Notes using proceeds from the December 2019 bond issuance.

3. Includes net impact of activity under our revolving credit facility (if any).

4. Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to finance the \$1,210M pending settlement of the U.S. Securities litigation due in 2021.

5. Excludes net legacy legal settlements (\$122M) and separation payments and separation-related payments (\$2M) for FY20.

6. Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to: (i) finance the \$1,210M pending settlement of the U.S. Securities litigation expected to be due in 2021 and (ii) replace \$1,240M of debt due May 2023 on Jan. 16, 2020.

7. See Slide 2 and Appendix for further non-GAAP information.

8. The guidance in this presentation is only effective as of the date given, Feb. 24, 2021, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following Feb. 24, 2021 does not constitute the Company re-affirming guidance.

9. Excludes legacy legal settlements (net of any insurance recovery), separation payments and separation-related payments

Balance Sheet Summary

	As of 12.31.20	As of 9.30.20	As of 6.30.20	As of 3.31.20	As of 12.31.19
Cash, cash equivalents and restricted cash	\$1,816M ¹	\$1,988M ¹	\$1,907M ¹	\$1,923M ¹	\$3,244M ²
Revolving Credit Drawn	\$0M	\$0M	\$0M	\$0M	\$0M
Senior Secured Debt ³	\$8,673M	\$8,948M	\$8,948M	\$10,541M	\$10,644M
Senior Unsecured Debt ³	\$15,512M	\$15,653M	\$15,681M	\$14,160M	\$15,544M
Total Debt ³	\$24,185M	\$24,601M	\$24,629M	\$24,701M	\$26,188M
Net Debt ⁴	\$23,580M ⁵	\$23,624M ⁶	\$23,733M ⁶	\$23,789M ⁶	\$22,945M ⁷
TTM ⁸ Adj. EBITDA (non-GAAP) ⁹	\$3,294M	\$3,281M	\$3,275M	\$3,533M	\$3,571M

- Repaid ~\$900M of debt in 2020 with cash generated from operations and more efficient cash management
- No debt maturities or mandatory amortization payments until 2024

1. Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to finance the \$1,210M pending settlement of the U.S. Securities litigation expected to be due in 2021.

2. Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to: (i) finance the \$1,210M pending settlement of the U.S. Securities litigation expected to be due in 2021 and (ii) replace \$1,240M of debt due May 2023 on Jan. 16, 2020.

3. Debt balances shown at principal value. Senior secured debt figure is inclusive of revolving credit drawn (if any).

4. Total Debt net of unrestricted cash and cash equivalents.

5. Restricted cash and cash equivalents as of 12/31/20 includes \$1,210M intended to be used to finance the pending settlement of the U.S. Securities litigation in 2021. This \$1,210M does not reduce net debt as of 12/31/20.

6. Restricted cash and cash equivalents as of 9/30/2020, 6/30/20 and 3/31/20 includes \$1,010M intended to be used to finance the \$1,210M pending settlement of the U.S. Securities litigation in 2021. This \$1,010M does not reduce net debt as of 9/30/2020, 6/30/20 and 3/31/20. Net Debt as of 9/30/2020, 6/30/20 and 3/31/20 is reduced by the remaining \$200M of the \$1,210M which is not in restricted cash.

7. Net Debt as of 12/31/19 is reduced by the \$1,210M, no part of which is in restricted cash as of 12/31/19, intended to be used to finance the pending settlement of the U.S. Securities litigation expected to be due in 2021.

8. Trailing Twelve Months.

9. See Slide 2 and Appendix for further non-GAAP information.

No Debt Maturities or Mandatory Amortization Until 2024

Long-Term Debt Maturity Profile as of December 31, 2020¹

	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	Total
Debt Maturities (Secured)	\$0	\$0	\$0	\$2,000M	\$5,768M	\$0	\$500M	\$0	\$0	\$0	\$0	\$8,268M
Debt Maturities (Unsecured)	\$0	\$0	\$0	\$0	\$4,750M	\$1,500M	\$1,750M	\$2,012M	\$3,250M	\$1,250M	\$1,000M	\$15,512M
Mandatory Amortization (Secured)	\$0	\$0	\$0	\$291M	\$114M	\$0	\$0	\$0	\$0	\$0	\$0	\$405M
Total	\$0	\$0	\$0	\$2,291M	\$10,632M	\$1,500M	\$2,250M	\$2,012M	\$3,250M	\$1,250M	\$1,000M	\$24,185M

- No debt maturities or mandatory amortization payments until 2024
- As of December 31, 2020, ~80% of debt is fixed rate debt; remaining ~20% is secured floating
- As of December 31, 2020, ~6.02% weighted average cost of debt, down from ~6.21% as of December 31, 2019
- For full year 2020, repaid ~\$900M of debt using cash generated from operations and more efficient cash management
- Subsequent to 2020, announced redemption of \$100M of 7.0% Senior Secured Notes due 2024 on March 24, 2021 with cash generated from operations

FY 2021 Guidance

Full-Year 2021 Revenue and Adjusted EBITDA (non-GAAP)¹ Guidance^{3,4}

	Current Guidance (February 2021)
Total Revenues	\$8.60B - \$8.80B
Adjusted EBITDA (non-GAAP) ¹	\$3.40B - \$3.55B

Key Assumptions	Current Guidance (February 2021)
Adj. SG&A Expense (non-GAAP) ¹	~\$2.6B
R&D Expense	~\$525M
Interest Expense ²	~\$1.46B
Adj. Tax Rate (non-GAAP) ¹	~7%
Avg. Fully Diluted Share Count	363M
Additional Non-Cash Assumptions	
Depreciation	~\$195M
Stock-Based Compensation	~\$115M
Additional Cash Item Assumptions	
Capital Expenditures ⁹	~\$275M
Contingent Consideration / Milestones / License Agreements	~\$175M
Restructuring and Other	~\$75M

Adj. cash generated from operations (non-GAAP)¹ for 2021 is expected to be ~\$1.5B⁵

Gross margin for 2021 is expected to be ~72%

3-year CAGRs^{6,8}
(constant currency and from the mid-point of 2019 guidance⁷)

- Expect revenue to grow at a 3%-5% CAGR⁶
- Expect adj. EBITDA (non-GAAP)¹ to grow at a 4%-7% CAGR⁶

Excluding divestitures, targeting ~\$1B of debt paydown in 2021

1. See Slide 2 and Appendix for further non-GAAP information.

2. Interest expense includes amortization and write-down of deferred financing costs of ~\$50M.

3. The guidance in this presentation is only effective as of the date given, Feb. 24, 2021, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following Feb. 24, 2021 does not constitute the Company re-affirming guidance.

4. See Slide 1 for further information on forward-looking statements.

5. Excludes legacy legal settlements (net of any insurance recovery), separation payments and separation-related payments


6. Compound Annual Growth Rate.

7. Based on Guidance issued in Feb. 2019.

8. Excludes the impact of the previously announced separation of the eye health business, including one-time costs, duplicative costs, and dis-synergies associated with such separation.

9. Does not include impact of spinoff.

Full-Year 2021 Revenue and Adjusted EBITDA (non-GAAP)¹ Guidance Bridge^{2,3}



Segment Results & Recovery

Execution, Growth & Accelerating Strategic Alternatives



**Executing Our
Business
Recovery from
COVID-19**




**Unleashing
Growth Drivers**



**Accelerating
Strategic
Alternatives to
Drive
Shareholder
Value**

Bausch + Lomb/International 4Q20 and FY20 Highlights

Bausch + Lomb/International Organic Growth^{1,2} (Y/Y)



Recovery in Progress

- Organic revenue^{1,2} recovered to pre-COVID-19 levels in 4Q20 vs. 4Q19
- Organic revenue decline^{1,2} of (6%) in FY20 vs. FY19, driven by COVID-19

Global Vision Care

- U.S. reported revenue growth of 2% vs. FY19 and 5% vs. 4Q19, driven by parameter expansions for Biotrue® ONEday and Bausch + Lomb ULTRA®
- International saw organic revenue^{1,2} decline of (17%) vs. FY19 and (3%) vs. 4Q19; drag on revenue was driven by Asia Pacific
- Launched SiHy daily as INFUSE® in U.S. and ULTRA® ONE DAY in Australia, Hong Kong and Canada

Global Consumer

- Ocuvite® + PreserVision® saw organic revenue growth^{1,2} of 7% vs. FY19 and organic revenue growth^{1,2} of 16% vs. 4Q19
- LUMIFY® reported \$74M in revenue in FY20 or reported revenue growth of 17% vs. FY19

Global Surgical

- Revenue and procedures approaching pre-pandemic levels
- Delayed cataract surgeries in 2020 create tailwind for 2021 and beyond

Global Ophtho Rx


- VYZULTA® saw >40% TRx growth in FY20 vs. FY19
- Market share gains seen across key promoted brands including VYZULTA®, LOTEMAX® SM and PROLENSA®

International Rx


- Saw 6% organic revenue growth^{1,2} vs. FY19; growth in FY20 driven by Ivermectin
- Organic revenue growth^{1,2} in nearly all countries during FY20, led by Mexico and Egypt

Bausch + Lomb/International Recovery Update


Bausch + Lomb U.S. Vision Care Dollar % Change Year-Over-Year (Field Consumption)¹



VYZULTA® TRx Trend²



U.S. Bausch + Lomb Consumer Consumption % Change Year-Over-Year³




LUMIFY®: Weekly Sales Trend³




Stellaris Elite™ Procedures in U.S. Performed Since Beginning of 2020

(data collected via eyeTelligence which accounts for ~40% of the Stellaris Elite™ systems within the U.S. market)




International Surgical Revenue⁵




Bausch + Lomb/International Market Share Gains


VYZULTA® TRx Market Share^{1,2}




LOTEMAX® SM TRx Market Share^{1,2}




PROLENSA® TRx Market Share^{1,2}



U.S. Bausch + Lomb IOL Market Share^{4,5,6}



U.S. Consumer Gaining Share in Key Segments (Dollar Share)⁷



1. IQVIA xPonent PlanTrak Monthly Data.

2. Market share based on our contracted payer market baskets (on file).

3. 2019 for Lotemax SM is from March 2019 (product launch month) through Dec 2019.

4. Market Scope's Manufacturer Survey.

5. IOLs include: enVista, enVista Toric, Akreos, Softport, Crystalens and Trulign.

6. Rolling four quarter share.


7. Consumer Data Science: Total US IRI Panel Data Ending 12-27-20.

BAUSCH + LOMB INFUSE™

U.S. Market Opportunity

- Launched into fastest growing category¹
- Estimated U.S. market is currently ~\$1B and expected to grow to ~\$3B in 2030^{4,5,7}

U.S. Daily Disposable Single Vision Spherical Dollar Sales by Material



Global Opportunity

- **Additional SiHy Daily Launches:** Launched AQUALOX® daily SiHy in Japan and Bausch + Lomb ULTRA® ONE DAY daily SiHy in Australia, Hong Kong and Canada
 - More countries coming in 2021, including Europe
- **Global revenue for Bausch + Lomb SiHy dailies is expected to exceed \$250M in sales⁷**

Initial Feedback



94% of patients surveyed agreed Bausch + Lomb INFUSE™ helps keep contact lenses from feeling dry⁶



94% of patients surveyed agreed they can comfortably wear Bausch + Lomb INFUSE™ contact lenses all day⁶



97% of patients surveyed agreed Bausch + Lomb INFUSE™ contact lenses provide crisp, clear vision throughout the day⁶

1. GfK U.S. Q3 2020 Contact Lens Retail Sales \$ Growth vs. prior year.

2. GfK U.S. 2019 Contact Lens Retail Sales \$ Share Daily Disposable Single Vision Spherical by Material.

3. 2030 B+L Brand Estimate, Daily Disposable Single Vision Spherical Retail Share (\$).

4. GfK U.S. 2019 Contact Lens Retail Sales \$ Daily Disposable Single Vision Spherical


5. 2020-2030 B+L Brand Estimate, Daily Disposable Single Vision Spherical Retail Sales (\$).

6. Results of an online survey with patients who completed an evaluation program for Bausch + Lomb INFUSE™ contact lenses and wore their trial lenses for ≥7 days (n=777). Survey results include patients who strongly agreed, agreed, or slightly agreed (on a 6-point agreement scale) with the surveyed statement, with a margin of error ±1.7%.

7. See Slide 1 for further information on forward-looking statements.

Salix 4Q20 and FY20 Highlights

Salix Organic Growth^{1,2} (Y/Y)



Recovery in Progress

- Organic revenue^{1,2} recovered to pre-COVID-19 levels in 4Q20 vs. 4Q19
- Organic revenue decline^{1,2} of (6%) in FY20 vs. FY19, driven by COVID-19

XIFAXAN®

- XIFAXAN® saw reported revenue growth of 2% in FY20 vs. FY19 and 4% in 4Q20 vs. 4Q19
- XIFAXAN® hit record high quarterly revenue during 4Q20; reported \$411M in quarterly revenue
- Recovery continued:** 2% TRx revenue growth in 4Q20 vs. 3Q20³
- Market share gains:** NRx market share grew to 85.8% in 4Q20 compared to 85.3% in 4Q19³

TRULANCE®

- TRULANCE® saw reported revenue growth of 49% in FY20 vs. FY19 and 33% in 4Q20 vs. 4Q19
- TRx growth of 47% in FY20 vs. FY19, compared to market growth of 6%³
- Increased NRx market share:** Commercial NRx market share moved from 5.5% at time of acquisition in March 2019 to 12.1% in December 2020⁴

RELISTOR®

- RELISTOR® saw reported revenue growth of 4% in FY20 vs. FY19 and 7% in 4Q20 vs. 4Q19
- TRx growth of 9% in FY20 vs. FY19, compared to market decline of 4%³
 - TRx growth driven by RELISTOR® oral which saw 14% TRx growth in FY20 vs. FY19³

1. See Slide 2 and Appendix for further non-GAAP information.


2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. IQVIA NPA monthly.


4. IQVIA Monthly Plantrak Data.

Salix Recovery Update


XIFAXAN® TRx Trend¹



TRULANCE® TRx Trend¹




RELISTOR® TRx Trend¹




- Gastroenterology experienced the second largest decline in patient diagnosis visits in 2020 compared to all other specialties²
- **Recovery in Progress:** The number of patient visits with a diagnosis to Gastroenterologists in April 2020 was 48% below pre-COVID levels compared to 15% below in December 2020²

Salix Market Share Gains


XIFAXAN® TRx Market Share^{1,2}



TRULANCE® TRx Market Share^{1,2}




RELISTOR® TRx Market Share^{1,2}



Increased TRULANCE® NRx market share: Commercial NRx market share moved from 5.5% at time of acquisition in March 2019 to 12.1% in December 2020¹

Ortho Dermatologics 4Q20 and FY20 Highlights

Global Solta Organic Growth^{1,2} (Y/Y)



Recovery in Progress

- Organic revenue^{1,2} recovered to pre-COVID-19 levels in 4Q20 vs. 4Q19
 - Driven by strong performance from Global Solta which saw organic revenue^{1,2} growth of 31%
- Organic revenue decline^{1,2} of (3%) in FY20 vs. FY19, driven by COVID-19

THERMAGE®

- Thermage® saw reported revenue growth of 47% in FY20 vs. FY19 and 46% in 4Q20 vs. 4Q19
 - Growth driven by China as well as expansion into new geographies
- Benefitting from trends that are driving aesthetics sales, such as an increase in “Zoom culture”, as well as consumers increasingly spending money on self-care
- 2021 Growth Catalysts:** Continued market penetration in China and U.S. as well as geo-expansion, including Europe
- 2021 Global Solta Launch:** Clear + Brilliant® Touch laser U.S. launch, a next generation Clear + Brilliant® laser

JUBLIA®


- JUBLIA® saw reported revenue growth of 3% in FY20 vs. FY19
- TRx growth of 18% in FY20 vs. FY19, compared to a flat market³

Additional Key Products


- DUOBRII® saw TRx growth of 53% in FY20 vs. FY19, compared to market growth of 5%³
- SILIQ® saw reported revenue growth of 39% in FY20 vs. FY19

Ortho Dermatologics Recovery and Market Share Gains


Thermage® Revenue¹




JULBIA® TRx Trend²




DUOBRII® TRx Trend³




DUOBRII® TRx Market Share^{4,5}



JULBIA® TRx Market Share^{4,5}



ONEXTON® TRx Market Share^{4,5}



1. Internal data.
 2. IQVIA NPA weekly.
 3. IQVIA NPA monthly.
 4. IQVIA xPonent PlanTrak Monthly Data.
 5. Market share based on our contracted payer market baskets (on file).
 6. 2019 for Duobrii® is from June 2019 (product launch month) through Dec 2019.

Driving Growth in 2021 & Beyond

Execution, Growth & Accelerating Strategic Alternatives



**Executing Our
Business
Recovery from
COVID-19**



**Unleashing
Growth Drivers**



**Accelerating
Strategic
Alternatives to
Drive
Shareholder
Value**

Unleashing Growth Drivers

Business Growth Drivers¹

- **SiHy daily:** Ramp up and approvals globally
- **Cataract surgery tailwind:**
 - In U.S., ~4M surgeries are performed each year²
 - In 2020, we estimate ~650K surgeries or ~16% in U.S. were delayed while outside the U.S. we estimate 20% of the surgeries were delayed, creating a potential tailwind for 2021 and beyond³
- Continued **global expansion** of our International Rx portfolio
- **Thermage® franchise:** Expansion of sales force into Europe
- **Strong performance and recovery** of leading brands:



Xifaxan®



thermage®
FLX



Trulance®
(plecanatide)



BAUSCH+LOMB
PreserVision®



LUMIFY®
REDNESS RELIEVER EYE DROPS



VYZULTA.
(latanoprostene
bunod ophthalmic
solution), 0.024%

Near-term Catalysts¹

R&D: Upcoming Milestones

- Initiate **Amiselimod** S1P² Modulator Phase 2 trial³ – **1H21**
- Readout of **topline results** of first of two Phase 3 trials for **NOV03**, an investigational treatment for dry eye disease associated with meibomian gland dysfunction⁴ – **2H21**
- Initiate Phase 3 trial for **rifaximin life cycle program RED-C** (prevention of cirrhosis complications – HE⁵) – **2H21**
- Initiate Phase 2 trial for **rifaximin life cycle program** including sickle cell – **2H21**
- Expect to complete enrollment for **Eyenovia** Phase 3 trial for reduction of pediatric myopia⁶ – **2H22**
- Expect to start Phase 3 trial for **Risuteganib (Luminate®)**¹¹, an investigational treatment expected to help reverse vision loss due to dry AMD^{8,9}



NOV03 SEECASE Study Published in *The Journal of Cornea and External Disease*⁷

- Study **met its primary endpoint**, change from baseline of tCFS¹⁰ over control, for both dosing regimens QID and BID (P < 0.001 and P = 0.009, respectively)
- NOV03 **showed pronounced improvement** in various symptoms
- For the Eye Dryness Score, **changes from baseline were statistically significant** compared with those of the control at week 8 [P < 0.001 (QID) and P = 0.002 (BID)]

COVID Focused Treatments

- **DEXAVEN® (dexamethasone phosphate)**: In December 2020, Poland granted an additional new indication for the treatment of COVID-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) who require oxygen therapy
- In vitro data showed three benzalkonium chloride (BAK) preserved eye drops, **LUMIFY®**, **BESIVANCE®** and **Opcon-A®** indicated **complete inactivation (achieved ≥ 3.0 log reduction) of COVID-19**
- **IVEXTERM™ (Ivermectin) studies ongoing in Latin America**: To assess the efficacy, safety, and tolerability in patients with mild COVID-19 and the progression rate to severe COVID-19 – **Topline data expected in 1H21**
- **VIRAZOLE® (ribavirin)**: Studied in investigational clinical trial in Canada, Greece, Mexico and Brazil to evaluate use in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19

1. See Slide 1 for further information on forward-looking statements.

2. Sphingosine 1-phosphate.

3. Exclusive licensing agreement with Mitsubishi Tanabe Pharma

4. Exclusive licensing agreement with Novaliq GmbH.

5. Hepatic encephalopathy.

6. Exclusive licensing agreement with Eyenvia, Inc.

7. https://journals.lww.com/corneajml/Abstract/9000/A_Randomized_Clinical_Study_SEECASE_to_Assess.95863.aspx.

8. Age-related Macular Degeneration.

9. Agreement to acquire all ophthalmology assets of Allegro.

10. Total corneal fluorescein staining.

11. Provisional name. Luminate® is a registered trademark of Allegro Ophthalmics.


2021 Strategic Focus: Execution, Growth & Accelerating Strategic Alternatives



**Executing Our
Business
Recovery from
COVID-19**



**Unleashing
Growth Drivers**



**Accelerating
Strategic
Alternatives to
Drive
Shareholder
Value**


Spinoff Update

Accelerating Strategic Alternatives to Expedite Spin-off¹

Noteworthy Milestones

- Financial segmentation of Bausch + Lomb anticipated to be complete by **1Q21**
- All internal objectives necessary for the spin of Bausch + Lomb anticipated to be achieved by **3Q21**

Potential Paths Forward:



Actively pursuing all opportunities to expedite leverage improvement and deliver shareholder value

The background is a grayscale image of a medical monitor. It displays various vital signs and waveforms. At the top left, there's a circular gauge labeled 'Flow cmH2O' with a needle pointing to 20. Next to it is a waveform labeled 'Scale changed'. On the right side, there's a digital display showing '11:53' and '3:11'. Below that, it shows '5.1' and '522'. At the bottom, there's a section with 'Pressure Control: Ventilator On', 'Pinsp cmH2O 10', 'RR /min 10', 'IE 1:2', and 'PEEP cmH2O Off'. There are also some other numbers like '0.70', '0.70', '1.40', and '0.8 1.1' visible on the screen.

Appendix

3-year CAGR^{1,2} (2019-2022)

Constant currency and from the original mid-point of 2019 guidance³

- Expect revenue to grow at a **3%-5% CAGR¹** at midpoint of original 2019 guidance of \$8,400M
- Expect adj. EBITDA (non-GAAP)⁴ to grow at a **4%-7% CAGR¹** at midpoint of original 2019 guidance of \$3,425M

Pipeline and Portfolio Expansion: Late Stage Development¹

BAUSCH + LOMB

- SiHy Daily – **Launched in Japan and U.S.; Launched in Australia, Hong Kong and Canada in 4Q20**
- LUMIFY® Line Extensions – **Phase 3 clinical studies expected to start in 1H21**
- Next Generation enVista® Optic Design Intraocular Lens - **Anticipated submission in U.S. and Europe in 2021**
- enVista® Trifocal (Intraocular Lens) – **Initiated IDE² study in May 2018; Initiated the last phase of this three phase study in 4Q20**
- Preloaded intraocular lens injector platform for enVista interocular lens – **Launched in U.S. and Europe in October 2020**
- New Ophthalmic Viscosurgical Device – **Filing of premarket approval application for dispersive OVD completed April 2020**
- XIPERE™³ (investigational treatment for macular edema associated with uveitis) – **Working closely with partner to resubmit NDA to FDA**
- Alaway® Preservative-Free (EM-100) (OTC preservative-free eye drop for the treatment of ocular itching associated with allergic conjunctivitis) – **Launched Feb. 2021**
- NOV03⁴ (dry eye disease associated with meibomian gland dysfunction) – **Expect readout of topline results from the first of two Phase 3 studies during the 2H21 and anticipate filing an NDA in 2022**
- Microdose formulation of atropine ophthalmic solution (reduction of pediatric myopia progression in children ages 3-12⁹ – **Phase 3 trial ongoing**
- Myopia control contact lens design¹⁰ licensed from BHVI
- Risuteganib (Luminate®)¹² (investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry AMD) - **Topline results of Phase 2 intermediate dry AMD clinical trial, met its primary endpoint; Phase 3 testing is in the planning stages¹¹**



- Amiselimod S1P⁵ Modulator⁶ – **Completed the thorough QT study which evaluated the cardiac safety profile; topline results were positive and expect to initiate Phase 2 study in 1H21**
- Rifaximin (OHE⁷) – **Topline data from our Phase 2 study for the treatment of OHE with a new formulation of rifaximin showed a treatment benefit; The topline results of this study will help inform further research on potential new indications for rifaximin using this new formulation.**
- Rifaximin (RED-C: prevention of cirrhosis complications – HE⁸) - **Phase 3 trial expected to start 2H21**
- Rifaximin (SIBO¹³) - **Phase 2 awaiting results of new formulation study that will be available in 1H21; Research on development of a Patient Reported Outcomes tool for SIBO is to continue in 2021**
- ENVIVE™ (Probiotic) – **Launched with a targeted group of gastroenterologists; Widely available in 1Q21**

Ortho | Dermatologics

- Clear + Brilliant® Touch laser (a next generation Clear + Brilliant® laser) - **U.S. launch 1H21**
- IDP-120 (Acne) – **Phase 3 completed and met primary endpoints; currently evaluating next steps for this program**
- ARAZLO® (formerly IDP-123 - Acne) – **Launched June 2020**
- IDP-126 (Acne Combination) – **First Phase 3 trial completed successfully. Evaluating next steps for second Phase 3 trial and additional trials**

1. See slide 1 for further information on forward-looking statements.
2. Investigational device exemption.
3. Exclusive licensing agreement with Clearside Biomedical, Inc.
4. Exclusive licensing agreement with Novaliq GmbH.
5. Sphingosine 1-phosphate.
6. Exclusive licensing agreement with Mitsubishi Tanabe Pharma.
7. Overt hepatic encephalopathy.

8. Hepatic encephalopathy.
9. Exclusive licensing agreement with Eyenovia, Inc.
10. Exclusive licensing agreement with BHVI.
11. Agreement to acquire all ophthalmology assets of Allegro.
12. Provisional name. Luminate® is a registered trademark of Allegro Ophthalmics.
13. Small intestinal bacterial overgrowth.

Key Product LOE Q4 2020 Impact

Business Unit	Product Line with Actual or Anticipated LOE Date ¹	LOE Rev/Profit Q4 2019 Actual		LOE Rev/Profit Q4 2020 Actual		Change Q4 2019 vs. Q4 2020	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	<ul style="list-style-type: none"> Lotemax Suspension® 2Q19 Lotemax Gel® 1Q21 (not date certain) 	\$14M	\$14M	\$6M	\$6M	(\$8M)	(\$8M)
Int'l	<ul style="list-style-type: none"> Glumetza® 1Q17 Tiazac® XC 2H 2021 (not date certain) Lodalis 1H 2021 (not date certain) 	\$12M	\$10M	\$12M	\$10M	\$0M	\$0M
BAUSCH + LOMB / INTERNATIONAL		\$26M	\$24M	\$18M	\$16M	(\$8M)	(\$8M)
SALIX	<ul style="list-style-type: none"> Zegerid® add't US Gx 2017 Uceris® 3Q18 Apriso® 4Q19 Moviprep® 3Q20 	\$35M	\$24M	\$29M	\$19M	(\$6M)	(\$5M)
ORTHO DERMATOLOGICS	<ul style="list-style-type: none"> Solodyn® 1Q18/19 Acanya® 3Q18 Elidel® 4Q18 Zovirax® (Cream) 1Q19 	\$6M	\$5M	(\$3M)	(\$5M)	(\$9M)	(\$10M)
DIVERSIFIED PRODUCTS	<ul style="list-style-type: none"> Xenazine® Gx and brand competition 2Q17 Isuprel® 3Q17 Syprine® 1Q18 Mephyton® 2Q18 Cuprimine® 2Q19 Migranal Franchise 2Q20 	\$39M	\$31M	\$15M	\$13M	(\$24M)	(\$18M)
OVERALL COMPANY		\$106M	\$84M	\$59M	\$43M	(\$47M)	(\$41M)

Key Product LOE 2020 Impact vs. Prior Forecast

Business Unit	Product Line with Actual or Anticipated LOE Date ¹	LOE Rev/Profit Prior Forecast		LOE Rev/Profit 2020 Actual		Change Actual vs Prior Forecast	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	<ul style="list-style-type: none"> Lotemax Suspension® 2Q19 Lotemax Gel® 1Q21 (not date certain) 	\$26M	\$25M	\$26M	\$25M	\$0M	\$0M
Int'l	<ul style="list-style-type: none"> Glumetza® 1Q17 Tiazac® XC 2H 2021 (not date certain) Lodalis 1H 2021 (not date certain) 	\$50M	\$39M	\$52M	\$41M	\$2M	\$2M
BAUSCH + LOMB / INTERNATIONAL		\$76M	\$64M	\$78M	\$66M	\$2M	\$2M
SALIX	<ul style="list-style-type: none"> Zegerid® add't US Gx 2017 Uceris® 3Q18 Apriso® 4Q19 Moviprep® 3Q20 	\$74M	\$55M	\$87M	\$62M	\$13M	\$7M
ORTHO DERMATOLOGICS	<ul style="list-style-type: none"> Solodyn® 1Q18/19 Acanya® 3Q18 Elidel® 4Q18 Zovirax® (Cream) 1Q19 	\$15M	\$10M	\$9M	\$4M	(\$6M)	(\$6M)
DIVERSIFIED PRODUCTS	<ul style="list-style-type: none"> Xenazine® Gx and brand competition 2Q17 Isuprel® 3Q17 Syprine® 1Q18 Mephyton® 2Q18 Cuprimine® 2Q19 Migranal Franchise 2Q20 	\$96M	\$86M	\$96M	\$86M	\$0M	\$0M
OVERALL COMPANY		\$261M	\$215M	\$270M	\$218M	\$9M	\$3M

1. Anticipated date of loss of exclusivity is based on the Company's current best estimate and actual date of LOE, as the case may be, may occur earlier or later. Changes from prior forecast are noted in red.

Key Product LOE 2020 Impact vs. 2019

Business Unit	Product Line with Actual or Anticipated LOE Date ¹	LOE Rev/Profit 2019 Actual		LOE Rev/Profit 2020 Actual		Change 2019 vs 2020	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	<ul style="list-style-type: none"> Lotemax Suspension® 2Q19 Lotemax Gel® 1Q21 (not date certain) 	\$87M	\$85M	\$26M	\$25M	(\$61M)	(\$60M)
Int'l	<ul style="list-style-type: none"> Glumetza® 1Q17 Tiazac® XC 2H 2021 (not date certain) Lodalis 1H 2021 (not date certain) 	\$45M	\$37M	\$52M	\$41M	\$7M	\$4M
BAUSCH + LOMB / INTERNATIONAL		\$132M	\$122M	\$78M	\$66M	(\$54M)	(\$56M)
SALIX	<ul style="list-style-type: none"> Zegerid® add't US Gx 2017 Uceris® 3Q18 Apriso® 4Q19 Moviprep® 3Q20 	\$196M	\$151M	\$87M	\$62M	(\$109M)	(\$89M)
ORTHO DERMATOLOGICS	<ul style="list-style-type: none"> Solodyn® 1Q18/19 Acanya® 3Q18 Elidel® 4Q18 Zovirax® (Cream) 1Q19 	\$46M	\$41M	\$9M	\$4M	(\$37M)	(\$37M)
DIVERSIFIED PRODUCTS	<ul style="list-style-type: none"> Xenazine® Gx and brand competition 2Q17 Isuprel® 3Q17 Syprine® 1Q18 Mephyton® 2Q18 Cuprimine® 2Q19 Migranal Franchise 2Q20 	\$194M	\$175M	\$96M	\$86M	(\$98M)	(\$89M)
OVERALL COMPANY		\$568M	\$489M	\$270M	\$218M	(\$298M)	(\$271M)

Key Product LOE 2021 Impact vs. 2020

Business Unit	Product Line with Actual or Anticipated LOE Date ¹	LOE Rev/Profit 2020 Actual		LOE Rev/Profit 2021 Forecast		Change 2020 vs 2021 Forecast	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	<ul style="list-style-type: none"> Lotemax Suspension® 2Q19 Lotemax Gel® 1Q21 Timoptic Ocudose 4Q20 Bepreve 2Q21 	\$59M	\$55M	\$30M	\$27M	(\$29M)	(\$28M)
Int'l	<ul style="list-style-type: none"> Glumetza® 1Q17 Tiazac® XC 2H 2021 (not date certain) Lodalix 1H 2021 (not date certain) 	\$52M	\$41M	\$48M	\$39M	(\$4M)	(\$2M)
BAUSCH + LOMB / INTERNATIONAL		\$111M	\$96M	\$78M	\$66M	(\$33M)	(\$30M)
SALIX	<ul style="list-style-type: none"> Zegerid® add't US Gx 2017 Uceris® 3Q18 Apriso® 4Q19 Moviprep® 3Q20 	\$87M	\$62M	\$63M	\$44M	(\$24M)	(\$18M)
ORTHO DERMATOLOGICS	<ul style="list-style-type: none"> Solodyn® 1Q18/19 Acanya® 3Q18 Elidel® 4Q18 Zovirax® (Cream) 1Q19 	\$9M	\$4M	\$11M	\$9M	\$2M	\$5M
DIVERSIFIED PRODUCTS	<ul style="list-style-type: none"> Xenazine® Gx and brand competition 2Q17 Isuprel® 3Q17 Syprine® 1Q18 Mephyton® 2Q18 Cuprimine® 2Q19 Migranal Franchise 2Q20 Demser 3Q20 	\$104M	\$94M	\$53M	\$44M	(\$51M)	(\$50M)
OVERALL COMPANY		\$311M	\$256M	\$205M	\$163M	(\$106M)	(\$93M)

Selected U.S. Businesses Pipeline Inventory Trending (4Q20)¹

Months on Hand						
Business Units	As of Sep 30, 2019	As of Dec 31, 2019	Change 4Q19	As of Sep 30, 2020	As of Dec 31, 2020	Change 4Q20
Derm	1.13	0.88	(0.25)	0.97	0.72	(0.25)
Neuro	1.01	0.83	(0.18)	1.10	0.56	(0.54)
Ophtho	0.81	0.71	(0.10)	0.85	0.73	(0.12)
GI	0.86	0.79	(0.07)	0.79	0.74	(0.05)

Selected U.S. Businesses Pipeline Inventory Trending (Year-to-Date)¹

Months on Hand						
Business Units	As of Dec 31, 2018	As of Dec 31, 2019	Change YTD19	As of Dec 31, 2019	As of Dec 31, 2020	Change YTD20
Derm	1.26	0.88	(0.38)	0.88	0.72	(0.16)
Neuro	1.08	0.83	(0.25)	0.83	0.56	(0.27)
Ophtho	0.89	0.71	(0.18)	0.71	0.73	0.02
GI	0.99	0.79	(0.20)	0.79	0.74	(0.05)

4Q 20

Financial Results

Bausch + Lomb/International

	Three Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Global Vision Care Revenue	\$213M	\$210M	1%	(1%)	(1%)
Global Surgical Revenue	\$182M	\$193M	(6%)	(8%)	(7%)
Global Consumer Revenue	\$386M	\$390M	(1%)	(1%)	(1%)
Global Ophtho Rx Revenue	\$139M	\$155M	(10%)	(12%)	(10%)
International Rx Revenue	\$322M	\$290M	11%	11%	12%
Total Segment Revenue	\$1,242M	\$1,238M	0%	0%	0%
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$720M	\$741M	(3%)	(3%)	
<i>Gross Margin</i>	<i>58.0%</i>	<i>59.9%</i>	<i>(190 bps)</i>		
Selling, A&P	\$312M	\$324M	4%	5%	
G&A	\$44M	\$45M	2%	2%	
R&D	\$35M	\$29M	(21%)	(24%)	
Total Operating Expense	\$391M	\$398M	2%	3%	
EBITA (non-GAAP)¹	\$329M	\$343M	(4%)	(3%)	
<i>EBITA Margin (non-GAAP)¹</i>	<i>26%</i>	<i>28%</i>			
Revenue % of total	56%	56%			
EBITA % (non-GAAP)¹ of total	39%	41%			

0%

Bausch + Lomb/International segment organic revenue change^{1,3} vs. 4Q19

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

4Q 20

Financial Results

Salix

	Three Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Salix Revenue	\$527M	\$517M	2%	2%	2%
Total Segment Revenue	\$527M	\$517M	2%	2%	2%
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$470M	\$458M	3%	3%	
Gross Margin	89.2%	88.6%	60 bps		
Selling, A&P	\$76M	\$80M	5%	5%	
G&A	\$13M	\$8M	(63%)	(63%)	
R&D	\$11M	\$16M	31%	31%	
Total Operating Expense	\$100M	\$104M	4%	4%	
EBITA (non-GAAP) ¹	\$370M	\$354M	5%	5%	
EBITA Margin (non-GAAP) ¹	70%	68%			
Revenue % of total	24%	23%			
EBITA % (non-GAAP) ¹ of total	44%	43%			

+2%

Salix segment organic revenue growth^{1,3} vs. 4Q19; in 4Q20, Salix had an LOE revenue drag of ~\$6M, primarily due to APRISO[®]

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

4Q 20

Financial Results

Ortho Dermatologics

	Three Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Ortho Dermatologics Revenue	\$73M	\$94M	(22%)	(22%)	(22%)
Global Solta Revenue	\$87M	\$64M	36%	31%	31%
Total Segment Revenue	\$160M	\$158M	1%	(1%)	(1%)
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$131M	\$132M	(1%)	(2%)	
<i>Gross Margin</i>	<i>81.9%</i>	<i>83.5%</i>	<i>(160 bps)</i>		
Selling, A&P	\$38M	\$50M	24%	24%	
G&A	\$8M	\$7M	(14%)	(14%)	
R&D	\$8M	\$9M	11%	11%	
Total Operating Expense	\$54M	\$66M	18%	18%	
EBITA (non-GAAP)¹	\$77M	\$66M	17%	14%	
<i>EBITA Margin (non-GAAP)¹</i>	<i>48%</i>	<i>42%</i>			
Revenue % of total	7%	7%			
EBITA % (non-GAAP)¹ of total	9%	8%			

+31%

Global Solta organic revenue increase^{1,3} vs. 4Q19, driven by continued strong demand of Thermage® FLX

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

4Q 20

Financial Results

Diversified Products

+6%

WELLBUTRIN^{®5}/APLENZIN[®] combined reported revenue growth vs. 4Q19; driven by WELLBUTRIN^{®5}, which saw 10% reported revenue growth vs. 4Q19

	Three Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Neuro & Other Revenue	\$160M	\$168M	(5%)	(5%)	(5%)
Generics Revenue	\$99M	\$117M	(15%)	(15%)	(15%)
Dentistry Revenue	\$25M	\$26M	(4%)	(4%)	(4%)
Total Segment Revenue	\$284M	\$311M	(9%)	(9%)	(9%)
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$247M	\$258M	(4%)	(4%)	
<i>Gross Margin</i>	87.0%	83.0%	400 bps		
Selling, A&P	\$23M	\$28M	18%	18%	
G&A	\$8M	\$11M	27%	27%	
R&D	\$2M	\$1M	(100%)	(100%)	
Total Operating Expense	\$33M	\$40M	18%	18%	
EBITA (non-GAAP)¹	\$214M	\$218M	(2%)	(2%)	
<i>EBITA Margin (non-GAAP)¹</i>	75%	70%			
Revenue % of total	13%	14%			
EBITA % (non-GAAP)¹ of total	25%	26%			

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets

5. U.S. sales only.

YTD 20

Financial Results

Bausch + Lomb/International

(6%)

Bausch + Lomb/International segment organic revenue decline^{1,3} vs. YTD19

	Twelve Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Global Vision Care Revenue	\$755M	\$848M	(11%)	(11%)	(11%)
Global Surgical Revenue	\$576M	\$698M	(17%)	(18%)	(17%)
Global Consumer Revenue	\$1,434M	\$1,455M	(1%)	0%	0%
Global Ophtho Rx Revenue	\$504M	\$638M	(21%)	(21%)	(20%)
International Rx Revenue	\$1,139M	\$1,100M	4%	5%	6%
Total Segment Revenue	\$4,408M	\$4,739M	(7%)	(6%)	(6%)
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$2,626M	\$2,926M	(10%)	(9%)	
<i>Gross Margin</i>	<i>59.6%</i>	<i>61.7%</i>	<i>(210 bps)</i>		
Selling, A&P	\$1,178M	\$1,294M	9%	8%	
G&A	\$166M	\$174M	5%	3%	
R&D	\$123M	\$126M	2%	2%	
Total Operating Expense	\$1,467M	\$1,594M	8%	7%	
EBITA (non-GAAP)¹	\$1,159M	\$1,332M	(13%)	(12%)	
<i>EBITA Margin (non-GAAP)¹</i>	<i>26%</i>	<i>28%</i>			
Revenue % of total	55%	55%			
EBITA % (non-GAAP)¹ of total	38%	41%			

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

YTD 20

Financial Results

Salix

	Twelve Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Salix Revenue	\$1,904M	\$2,022M	(6%)	(6%)	(6%)
Total Segment Revenue	\$1,904M	\$2,022M	(6%)	(6%)	(6%)
Adj. Gross Profit (non-GAAP) ^{1,4,5} (excluding amortization and impairments of intangible assets)	\$1,706M	\$1,767M	(3%)	(3%)	
Adj. Gross Margin (non-GAAP) ^{1,5}	89.6%	87.4%	220 bps		
Selling, A&P	\$277M	\$323M	14%	14%	
G&A	\$56M	\$54M	(4%)	(4%)	
R&D	\$35M	\$36M	3%	3%	
Total Operating Expense	\$368M	\$413M	11%	11%	
Adj. EBITA (non-GAAP) ^{1,5}	\$1,338M	\$1,354M	(1%)	(1%)	
Adj. EBITA Margin (non-GAAP) ^{1,5}	70%	67%			
Revenue % of total	24%	23%			
Adj. EBITA % (non-GAAP) ^{1,5} of total	44%	41%			

(6%)

Salix segment organic revenue decline^{1,3} vs. YTD19, partially offset by XIFAXAN[®] which reported 2% revenue growth; in FY20, Salix had an LOE revenue drag of \$109M, primarily due to APRISO[®]

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

5. 2020 numbers are on an as reported basis, no adjustments reflected in 2020.

YTD 20

Financial Results

Ortho Dermatologics

	Twelve Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Ortho Dermatologics Revenue	\$300M	\$371M	(19%)	(19%)	(19%)
Global Solta Revenue	\$253M	\$194M	30%	29%	29%
Total Segment Revenue	\$553M	\$565M	(2%)	(3%)	(3%)
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$452M	\$478M	(5%)	(6%)	
<i>Gross Margin</i>	<i>81.7%</i>	<i>84.6%</i>	<i>(290 bps)</i>		
Selling, A&P	\$157M	\$191M	18%	18%	
G&A	\$32M	\$27M	(19%)	(19%)	
R&D	\$30M	\$38M	21%	21%	
Total Operating Expense	\$219M	\$256M	14%	14%	
EBITA (non-GAAP)¹	\$233M	\$222M	5%	4%	
<i>EBITA Margin (non-GAAP)¹</i>	<i>42%</i>	<i>39%</i>			
Revenue % of total	7%	7%			
EBITA % (non-GAAP)¹ of total	8%	7%			

+29%

Global Solta organic revenue growth^{1,3} vs. YTD19, driven by continued strong demand of Thermage® FLX

FY20, Ortho Dermatologics business unit had an LOE revenue drag of \$37M; LOE was primarily ELIDEL® and ZOVIRAX®

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets.

YTD 20

Financial Results

Diversified Products

+13%

WELLBUTRIN^{®5}/APLENZIN[®] combined reported revenue growth vs. YTD19; driven by **WELLBUTRIN[®]**, which saw 11% reported revenue growth vs. FY19

FY20, Diversified Products business unit had an LOE revenue drag of \$98M; LOE was primarily **CUPRIMINE[®]** and **MIGRANAL[®]**

	Twelve Months Ended		Favorable (Unfavorable)		
	12.31.20	12.31.19	Reported	Constant Currency ^{1,2}	Organic Change ^{1,3}
Neuro & Other Revenue	\$674M	\$715M	(6%)	(6%)	(6%)
Generics Revenue	\$415M	\$459M	(10%)	(10%)	(10%)
Dentistry Revenue	\$73M	\$101M	(28%)	(28%)	(28%)
Total Segment Revenue	\$1,162M	\$1,275M	(9%)	(9%)	(9%)
Gross Profit⁴ (excluding amortization and impairments of intangible assets)	\$994M	\$1,085M	(8%)	(8%)	
<i>Gross Margin</i>	85.5%	85.1%	40 bps		
Selling, A&P	\$96M	\$105M	9%	9%	
G&A	\$42M	\$35M	(20%)	(20%)	
R&D	\$8M	\$13M	38%	38%	
Total Operating Expense	\$146M	\$153M	5%	5%	
EBITA (non-GAAP)¹	\$848M	\$932M	(9%)	(9%)	
<i>EBITA Margin (non-GAAP)¹</i>	73%	73%			
Revenue % of total	14%	15%			
EBITA % (non-GAAP)¹ of total	28%	28%			

1. See Slide 2 and Appendix for further non-GAAP information.

2. See Appendix for further information on the use and calculation of constant currency.

3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

4. See the Appendix for details on amortization and impairments of intangible assets

5. U.S. sales only.

Other Financial Information (Quarter-to-Date)

	Three Months Ended		Favorable (Unfavorable)	
	Dec. 31, 2020	Dec. 31, 2019	Reported	Constant Currency ^{1,2}
Cash Interest Expense	\$363M	\$374M	3%	3%
Net Interest Expense	\$377M	\$388M	3%	3%
Non-cash adjustments				
Depreciation	\$46M	\$47M	2%	4%
Non-cash share-based Comp	\$24M	\$25M	4%	4%
Additional cash items				
Contingent Consideration	\$6M	\$8M		
Milestones/License Agreements and Other Intangibles	\$16M	\$12M		
Restructuring and Other	\$98M	\$14M		
Capital Expenditures	\$80M	\$78M		
Adj. Tax Rate ¹	(3.2%)	7.8%		

Other Financial Information (Year-to-Date)

	Twelve Months Ended		Favorable (Unfavorable)	
	Dec. 31, 2020	Dec. 31, 2019	Reported	Constant Currency ^{1,2}
Cash Interest Expense	\$1,473M	\$1,549M	5%	5%
Net Interest Expense	\$1,521M	\$1,600M	5%	5%
Non-cash adjustments				
Depreciation	\$180M	\$178M	(1%)	(1%)
Non-cash share-based Comp	\$105M	\$102M	(3%)	(3%)
Additional cash items				
Contingent Consideration	\$36M	\$36M		
Milestones/License Agreements and Other Intangibles	\$67M	\$22M		
Restructuring and Other	\$213M	\$52M		
Capital Expenditures	\$302M	\$270M		
Adj. Tax Rate ¹	4.0%	7.8%		

1. See Slide 2 and this Appendix for further non-GAAP information.

2. See this Appendix for further information on the use and calculation of constant currency.

FY 20

Top 10 Products – Total BAUSCH Health¹

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	FY20	4Q20	3Q20	2Q20	1Q20	FY19	4Q19
1	XIFAXAN [®]	\$1,482M	\$411M	\$381M	\$315M	\$375M	\$1,452M	\$396M
2	Ocuvite [®] + PreserVision [®]	\$333M	\$100M	\$83M	\$78M	\$72M	\$313M	\$86M
3	WELLBUTRIN [®]	\$281M	\$70M	\$83M	\$66M	\$62M	\$269M	\$64M
4	SofLens [®]	\$236M	\$68M	\$63M	\$47M	\$58M	\$284M	\$70M
5	Thermage [®]	\$210M	\$70M	\$62M	\$37M	\$41M	\$143M	\$48M
6	renu [®]	\$174M	\$50M	\$45M	\$37M	\$42M	\$217M	\$62M
7	Biotrue [®] ONEday	\$164M	\$41M	\$51M	\$25M	\$47M	\$178M	\$40M
8	Bausch + Lomb ULTRA [®]	\$143M	\$38M	\$44M	\$21M	\$40M	\$130M	\$35M
9	Biotrue [®] Multi-Purpose Solution	\$131M	\$35M	\$34M	\$28M	\$34M	\$135M	\$37M
10	Relistor [®]	\$118M	\$30M	\$29M	\$27M	\$32M	\$112M	\$27M

FY 20

Top 10 Products – B+L/International

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	FY20	4Q20	3Q20	2Q20	1Q20	FY19	4Q19
1	Ocuvite® + PreserVision®	\$333M	\$100M	\$83M	\$78M	\$72M	\$313M	\$86M
2	SofLens®	\$236M	\$68M	\$63M	\$47M	\$58M	\$284M	\$70M
3	renu®	\$174M	\$50M	\$45M	\$37M	\$42M	\$217M	\$62M
4	Biotrue® ONEday	\$164M	\$41M	\$51M	\$25M	\$47M	\$178M	\$40M
5	Bausch + Lomb ULTRA®	\$143M	\$38M	\$44M	\$21M	\$40M	\$130M	\$35M
6	Biotrue® Multi-Purpose Solution	\$131M	\$35M	\$34M	\$28M	\$34M	\$135M	\$37M
7	ARTELAC®	\$95M	\$27M	\$23M	\$23M	\$22M	\$94M	\$24M
8	PureVision®	\$91M	\$25M	\$24M	\$18M	\$24M	\$109M	\$26M
9	Anterior Disposables®	\$81M	\$27M	\$21M	\$10M	\$23M	\$100M	\$27M
10	Boston Solutions®	\$76M	\$18M	\$18M	\$17M	\$23M	\$75M	\$20M

FY 20

Top 10 Products – Salix¹

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	FY20	4Q20	3Q20	2Q20	1Q20	FY19	4Q19
1	XIFAXAN [®]	\$1,482M	\$411M	\$381M	\$315M	\$375M	\$1,452M	\$396M
2	RELISTOR [®]	\$114M	\$29M	\$28M	\$26M	\$31M	\$110M	\$27M
3	TRULANCE [®]	\$82M	\$24M	\$22M	\$17M	\$19M	\$55M	\$18M
4	GLUMETZA [®]	\$75M	\$17M	\$20M	\$17M	\$21M	\$145M	\$24M
5	APRISO [®]	\$46M	\$14M	\$14M	\$11M	\$7M	\$145M	\$25M
6	UCERIS [®]	\$27M	\$10M	\$7M	\$4M	\$6M	\$32M	\$7M
7	ZEGERID [®]	\$14M	\$2M	\$5M	\$3M	\$4M	\$16M	\$4M
8	CYCLOSET [®]	\$13M	\$3M	\$4M	\$3M	\$3M	\$13M	\$3M
9	PLENVU [®]	\$13M	\$5M	\$4M	\$1M	\$3M	\$12M	\$4M
10	AZASAN [®]	\$10M	\$2M	\$3M	\$3M	\$2M	\$10M	\$2M

FY 20

Top 10 Products – Ortho Dermatologics

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	FY20	4Q20	3Q20	2Q20	1Q20	FY19	4Q19
1	THERMAGE®	\$210M	\$70M	\$62M	\$37M	\$41M	\$143M	\$48M
2	JUBLIA®	\$69M	\$13M	\$21M	\$16M	\$19M	\$67M	\$19M
3	SILIQ®	\$39M	\$9M	\$11M	\$12M	\$7M	\$28M	\$7M
4	TARGRETIN®	\$31M	\$9M	\$8M	\$7M	\$7M	\$44M	\$15M
5	RETIN-A® ¹	\$24M	\$7M	\$2M	\$4M	\$11M	\$24M	\$6M
6	ONEXTON®	\$22M	\$6M	\$6M	\$4M	\$6M	\$31M	\$5M
7	RETIN-A MICRO®.06 & .08	\$20M	\$5M	\$3M	\$4M	\$8M	\$37M	\$7M
8	VASER®	\$16M	\$6M	\$4M	\$2M	\$4M	\$18M	\$5M
9	CLINDAGEL®	\$15M	\$4M	\$3M	\$3M	\$5M	\$20M	\$5M
10	CLEAR & BRILLIANT®	\$13M	\$5M	\$4M	\$1M	\$3M	\$18M	\$6M

FY 20

Top 10 Products – Diversified Products¹

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	FY20	4Q20	3Q20	2Q20	1Q20	FY19	4Q19
1	WELLBUTRIN [®]	\$271M	\$67M	\$81M	\$65M	\$58M	\$244M	\$61M
2	APLENZIN [®]	\$98M	\$23M	\$26M	\$23M	\$26M	\$83M	\$24M
3	ARESTIN [®]	\$63M	\$21M	\$17M	\$6M	\$19M	\$87M	\$23M
4	ATIVAN [®]	\$50M	\$13M	\$22M	\$7M	\$8M	\$43M	\$9M
5	NEO/POLY/HC OTIC [®]	\$35M	\$4M	\$15M	\$7M	\$9M	\$22M	\$5M
6	TOBRAMYCIN/ DEXAMETHASONE	\$33M	\$6M	\$8M	\$11M	\$8M	\$31M	\$8M
7	PEPCID [®]	\$31M	\$12M	\$11M	\$5M	\$3M	\$2M	\$1M
8	DIASTAT [®]	\$30M	\$8M	\$8M	\$3M	\$11M	\$35M	\$10M
9	LIBRAX [®]	\$30M	\$14M	\$5M	\$5M	\$6M	\$25M	\$4M
10	XENAZINE [®]	\$29M	\$6M	\$7M	\$8M	\$8M	\$38M	\$9M

Non-GAAP Adjustments EPS Impact (\$M)²

	Three Months Ended December 31,				Twelve Months Ended December 31,			
	2020		2019		2020		2019	
	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per Share Impact
Net loss attributable to Bausch Health Companies Inc.	\$ (153)	\$ (0.43)	\$ (1,516)	\$ (4.30)	\$ (560)	\$ (1.58)	\$ (1,788)	\$ (5.08)
Non-GAAP adjustments:								
Amortization of intangible assets	382	1.06	445	1.24	1,645	4.59	1,897	5.31
Asset impairments, including loss on assets held for sale	97	0.27	26	0.07	114	0.32	75	0.21
Restructuring and integration costs	(1)	-	3	0.01	11	0.03	31	0.09
Acquired in-process research and development costs	12	0.03	32	0.09	32	0.09	41	0.11
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	22	0.06	10	0.03	48	0.13	25	0.07
Loss on extinguishment of debt	8	0.02	2	0.01	59	0.16	42	0.12
IT infrastructure investment	5	0.01	9	0.03	21	0.06	24	0.07
Separation and separation-related costs	27	0.08	-	-	32	0.09	-	-
Legal and other professional fees	11	0.03	13	0.04	39	0.11	35	0.10
Net gain on sale of assets	-	-	(21)	(0.06)	(1)	-	(31)	(0.09)
Litigation and other matters	295	0.82	1,389	3.87	422	1.18	1,401	3.92
Other	1	-	(1)	-	1	-	(7)	(0.02)
Tax effect of non-GAAP adjustments	(228)	(0.64)	13	0.04	(435)	(1.21)	(186)	(0.52)
EPS difference between basic and diluted shares		0.02		0.05		0.02		0.07
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)¹	\$ 478		\$ 404		\$ 1,428		\$ 1,559	

1. See Slide 2 and this Appendix for further non-GAAP information.

2. Except per share amounts..

Bausch + Lomb/Int'l Segment Trailing Five Quarters¹

Bausch + Lomb/International	FY20	4Q20	3Q20	2Q20	1Q20	4Q19
<i>Global Vision Care Revenue</i>	\$755M	\$213M	\$214M	\$135M	\$193M	\$210M
<i>Global Surgical Revenue</i>	\$576M	\$182M	\$151M	\$90M	\$153M	\$193M
<i>Global Consumer Revenue</i>	\$1,434M	\$386M	\$374M	\$321M	\$353M	\$390M
<i>Global Ophtho Rx Revenue</i>	\$504M	\$139M	\$136M	\$97M	\$132M	\$155M
<i>International Rx Revenue</i>	\$1,139M	\$322M	\$294M	\$240M	\$283M	\$290M
Segment Revenue	\$4,408M	\$1,242M	\$1,169M	\$883M	\$1,114M	\$1,238M
Segment Gross Profit³ (excluding amortization and impairments of intangible assets)	\$2,626M	\$720M	\$701M	\$495M	\$710M	\$741M
Segment Gross Margin	59.6%	58.0%	60.0%	56.1%	63.7%	59.9%
Segment R&D	\$123M	\$35M	\$30M	\$28M	\$30M	\$29M
Segment SG&A	\$1,344M	\$356M	\$335M	\$298M	\$355M	\$369M
Segment Profit/EBITA (non-GAAP)²	\$1,159M	\$329M	\$336M	\$169M	\$325M	\$343M

Salix Segment Trailing Five Quarters

Salix	FY20	4Q20	3Q20	2Q20	1Q20	4Q19
Salix Revenue	\$1,904M	\$527M	\$496M	\$404M	\$477M	\$517M
Segment Revenue	\$1,904M	\$527M	\$496M	\$404M	\$477M	\$517M
Segment Gross Profit ² (excluding amortization and impairments of intangible assets)	\$1,706M	\$470M	\$448M	\$364M	\$424M	\$458M
Segment Gross Margin	89.6%	89.2%	90.3%	90.1%	88.9%	88.6%
Segment R&D	\$35M	\$11M	\$6M	\$6M	\$12M	\$16M
Segment SG&A	\$333M	\$89M	\$82M	\$69M	\$93M	\$88M
Segment Profit/EBITA (non-GAAP) ¹	\$1,338M	\$370M	\$360M	\$289M	\$319M	\$354M

1. See Slide 2 and this Appendix for further non-GAAP information.
2. See this Appendix for details on amortization and impairments of intangible assets

Ortho Dermatologics Segment Trailing Five Quarters¹

Ortho Dermatologics	FY20	4Q20	3Q20	2Q20	1Q20	4Q19
<i>Ortho Dermatologics Revenue</i>	\$300M	\$73M	\$71M	\$74M	\$82M	\$94M
<i>Global Solta Revenue¹</i>	\$253M	\$87M	\$73M	\$42M	\$51M	\$64M
Segment Revenue	\$553M	\$160M	\$144M	\$116M	\$133M	\$158M
Segment Gross Profit³ (excluding amortization and impairments of intangible assets)	\$452M	\$131M	\$117M	\$91M	\$113M	\$132M
Segment Gross Margin	81.7%	81.9%	81.3%	78.4%	85.0%	83.5%
Segment R&D	\$30M	\$8M	\$5M	\$8M	\$9M	\$9M
Segment SG&A	\$189M	\$46M	\$42M	\$45M	\$56M	\$57M
Segment Profit/EBITA (non-GAAP)²	\$233M	\$77M	\$70M	\$38M	\$48M	\$66M

1. Products with sales outside the United States impacted by F/X changes.

2. See Slide 2 and this Appendix for further non-GAAP information.

3. See this Appendix for details on amortization and impairments of intangible assets.

Diversified Products Segment Trailing Five Quarters

Diversified Products	FY20	4Q20	3Q20	2Q20	1Q20	4Q19
<i>Neuro & Other Revenue</i>	\$674M	\$160M	\$199M	\$153M	\$162M	\$168M
<i>Generics Revenue</i>	\$415M	\$99M	\$111M	\$100M	\$105M	\$117M
<i>Dentistry Revenue</i>	\$73M	\$25M	\$19M	\$8M	\$21M	\$26M
Segment Revenue	\$1,162M	\$284M	\$329M	\$261M	\$288M	\$311M
Segment Gross Profit² (excluding amortization and impairments of intangible assets)	\$994M	\$247M	\$283M	\$218M	\$246M	\$258M
Segment Gross Margin	85.5%	87.0%	86.0%	83.5%	85.4%	83.0%
Segment R&D	\$8M	\$2M	\$2M	\$2M	\$2M	\$1M
Segment SG&A	\$138M	\$31M	\$33M	\$32M	\$42M	\$39M
Segment Profit/EBITA (non-GAAP)¹	\$848M	\$214M	\$248M	\$184M	\$202M	\$218M

1. See Slide 2 and this Appendix for further non-GAAP information.

2. See this Appendix for details on amortization and impairments of intangible assets.

Reconciliation of Reported Operating Income to Adjusted EBITA (non-GAAP)¹ (\$M) (Quarter-to-Date)

		Q4 2020						
		Gross Profit ²	Gross Margin ²	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 4 2020 GAAP		\$ 1,568	70.9%	\$ 448	\$ 188	\$ 119	\$ 755	\$ (5)
Amortization of finite-lived intangibles			0.0%				-	382
Asset impairments, including loss on assets held for sale			0.0%				-	97
Restructuring and integration costs			0.0%				-	(1)
Acquired in-process research and development costs			0.0%				-	12
Acquisition-related costs and adjustments (excluding amortization of intangible assets)			0.0%				-	22
IT infrastructure investment			0.0%		(5)		(5)	5
Separation and separation-related costs			0.0%		(17)		(17)	27
Legal and other professional fees			0.0%		(11)		(11)	11
Litigation and other matters			0.0%				-	295
Other non-GAAP charges			0.0%				-	1
Qtr 4 2020 Non-GAAP¹		\$ 1,568	70.9%	\$ 448	\$ 155	\$ 119	\$ 722	\$ 846

		Q4 2019						
		Gross Profit ²	Gross Margin ²	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 4 2019 GAAP		\$ 1,589	71.4%	\$ 483	\$ 185	\$ 114	\$ 782	\$ (1,076)
Amortization of finite-lived intangibles			0.0%				-	445
Asset impairments, including loss on assets held for sale			0.0%				-	26
Restructuring and integration costs			0.0%				-	3
Acquired in-process research and development costs			0.0%				-	32
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		-	0.0%				-	10
IT infrastructure investment			0.0%		(9)		(9)	9
Legal and other professional fees			0.0%		(13)		(13)	13
Net gain on sale of assets			0.0%				-	(21)
Litigation and other matters			0.0%				-	1,389
Other non-GAAP charges			0.0%				-	(1)
Qtr 4 2019 Non-GAAP¹		\$ 1,589	71.4%	\$ 483	\$ 163	\$ 114	\$ 760	\$ 829

1. See Slide 2 and this Appendix for further non-GAAP information.

2. Excluding amortization and impairments of intangible assets.

Reconciliation of Reported Operating Income to Adjusted EBITA (non-GAAP)¹ (\$M) (Year-to-Date)

YTD 2020							
	Gross Profit ²	Gross Margin ²	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
YTD 2020 GAAP	\$ 5,778	72.0%	\$ 1,707	\$ 660	\$ 452	\$ 2,819	\$ 676
Amortization of finite-lived intangibles		0.0%				-	1,645
Asset impairments, including loss on assets held for sale		0.0%				-	114
Restructuring and integration costs		0.0%				-	11
Acquired in-process research and development costs		0.0%				-	32
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		0.0%				-	48
IT infrastructure investment		0.0%		(21)		(21)	21
Separation and separation-related costs				(21)		(21)	32
Legal and other professional fees		0.0%		(39)		(39)	39
Net gain on sale of assets		0.0%				-	(1)
Litigation and other matters		0.0%				-	422
Other non-GAAP charges		0.0%		-		-	1
YTD 2020 Non-GAAP¹	\$ 5,778	72.0%	\$ 1,707	\$ 579	\$ 452	\$ 2,738	\$ 3,040

YTD 2019							
	Gross Profit ²	Gross Margin ²	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
YTD 2019 GAAP	\$ 6,251	72.7%	\$ 1,913	\$ 641	\$ 471	\$ 3,025	\$ (203)
Amortization of finite-lived intangibles		0.0%				-	1,897
Asset impairments, including loss on assets held for sale		0.0%				-	75
Restructuring and integration costs		0.0%				-	31
Acquired in-process research and development costs		0.0%				-	41
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	5	0.0%				-	25
IT infrastructure investment		0.0%		(24)		(24)	24
Legal and other professional fees		0.0%		(35)		(35)	35
Net gain on sale of assets		0.0%				-	(31)
Litigation and other matters		0.0%				-	1,401
Other non-GAAP charges		0.0%		2		2	(7)
YTD 2019 Non-GAAP¹	\$ 6,256	72.7%	\$ 1,913	\$ 584	\$ 471	\$ 2,968	\$ 3,288

1. See Slide 2 and this Appendix for further non-GAAP information.
2. Excluding amortization and impairments of intangible assets.

Amortization and Impairments of Intangible Assets (\$M)

	Amortization of intangible assets					Amortization of intangible assets	
	Q4 2020	Q3 2020	Q2 2020	Q1 2020	Q4 2019	YTD 2020	YTD 2019
Bausch + Lomb / International	\$ 103	\$ 111	\$ 110	\$ 110	\$ 111	\$ 434	\$ 464
Salix	194	194	246	246	246	880	981
Ortho Dermatologics	39	40	41	41	48	161	267
Diversified Products	46	46	39	39	40	170	185
Total Company	\$ 382	\$ 391	\$ 436	\$ 436	\$ 445	\$ 1,645	\$ 1,897

	Asset impairments					Asset impairments	
	Q4 2020 ¹	Q3 2020	Q2 2020	Q1 2020	Q4 2019	YTD 2020 ¹	YTD 2019
Bausch + Lomb / International	\$ 97	\$ -	\$ 1	\$ -	\$ 13	\$ 98	\$ 22
Salix	-	-	-	-	-	-	-
Ortho Dermatologics	-	-	-	-	13	-	13
Diversified Products	-	2	-	14	-	16	40
Total Company	\$ 97	\$ 2	\$ 1	\$ 14	\$ 26	\$ 114	\$ 75

1. Asset impairments includes loss on assets held for sale of \$96M.

Reconciliation of Reported Operating Income to Adjusted EBITA (non-GAAP)¹ (\$M) (Year-to-Date)

YTD 2019 GAAP

Acquisition-related costs and adjustments
excluding amortization and depreciation

YTD 2019 Non-GAAP¹

YTD 2019						
Salix						
Gross Profit ²	Gross Margin ²	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
\$ 1,762	87.1%	\$ 323	\$ 54	\$ 36	\$ 413	\$ 1,349
5	0.3%				-	5
\$ 1,767	87.4%	\$ 323	\$ 54	\$ 36	\$ 413	\$ 1,354

1. See Slide 2 and this Appendix for further non-GAAP information.

2. Excluding amortization and impairments of intangible assets.

Reconciliation of Reported Net Loss to EBITDA (non-GAAP)¹ and Adjusted EBITDA (non-GAAP)¹ (\$M)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2020	2019	2020	2019
Net loss attributable to Bausch Health Companies Inc.	\$ (153)	\$ (1,516)	\$ (560)	\$ (1,788)
Interest expense, net	377	388	1,521	1,600
(Benefit from) provision for income taxes	(242)	47	(375)	(54)
Depreciation and amortization	428	492	1,825	2,075
EBITDA	410	(589)	2,411	1,833
Adjustments:				
Asset impairments, including loss on assets held for sale	97	26	114	75
Restructuring and integration costs	(1)	3	11	31
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	22	10	48	25
Loss on extinguishment of debt	8	2	59	42
Share-based compensation	24	25	105	102
Separation and separation-related costs	27	-	32	-
Other adjustments:				
Litigation and other matters	295	1,389	422	1,401
IT infrastructure investment	5	9	21	24
Legal and other professional fees	11	13	39	35
Net gain on sale of assets	-	(21)	(1)	(31)
Acquired in-process research and development costs	12	32	32	41
Other	1	(1)	1	(7)
Adjusted EBITDA (non-GAAP)¹	\$ 911	\$ 898	\$ 3,294	\$ 3,571

Reconciliation of Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M) (Quarter-to-Date)

	Calculation of Organic Revenue for the Three Months Ended							Change in Organic Revenue	
	December 31, 2020				December 31, 2019			Amount	Pct.
	Revenue as Reported	Changes in Exchange Rates ³	Acquisition	Organic Revenue (Non-GAAP) ^{1,2}	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ^{1,2}		
Bauch +Lomb / International									
Global Vision Care	213	(5)	-	208	210	-	210	(2)	-1%
Global Surgical	182	(5)	-	177	193	(2)	191	(14)	-7%
Global Consumer Products	386	2	-	388	390	-	390	(2)	-1%
Global Ophtho Rx	139	(2)	-	137	155	(2)	153	(16)	-10%
International Rx	322	1	-	323	290	(1)	289	34	12%
Total Bausch + Lomb / International	1,242	(9)	-	1,233	1,238	(5)	1,233	-	0%
Salix									
Salix	527	-	-	527	517	-	517	10	2%
Ortho Dermatologics									
Ortho Dermatologics	73	-	-	73	94	-	94	(21)	-22%
Global Solta	87	(3)	-	84	64	-	64	20	31%
Total Ortho Dermatologics	160	(3)	-	157	158	-	158	(1)	-1%
Diversified Products									
Neurology & Other	160	-	-	160	168	-	168	(8)	-5%
Generics	99	-	-	99	117	-	117	(18)	-15%
Dentistry	25	-	-	25	26	-	26	(1)	-4%
Total Diversified Products	284	-	-	284	311	-	311	(27)	-9%
Total revenues	\$ 2,213	\$ (12)	\$ -	\$ 2,201	\$ 2,224	\$ (5)	\$ 2,219	\$ (18)	-1%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M) (Year-to-Date)

	Calculation of Organic Revenue for the Twelve Months Ended							Change in	
	December 31, 2020				December 31, 2019			Organic Revenue	
	Revenue as Reported	Changes in Exchange Rates ³	Acquisition	Organic Revenue (Non- GAAP) ^{1,2}	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non- GAAP) ^{1,2}	Amount	Pct.
Bauch +Lomb / International									
Global Vision Care	755	(1)	-	754	848	(1)	847	(93)	-11%
Global Surgical	576	(2)	-	574	698	(5)	693	(119)	-17%
Global Consumer Products	1,434	24	-	1,458	1,455	(2)	1,453	5	0%
Global Ophtho Rx	504	1	-	505	638	(7)	631	(126)	-20%
International Rx	1,139	20	-	1,159	1,100	(4)	1,096	63	6%
Total Bausch + Lomb / International	4,408	42	-	4,450	4,739	(19)	4,720	(270)	-6%
Salix									
Salix	1,904	-	(13)	1,891	2,022	-	2,022	(131)	-6%
Ortho Dermatologics									
Ortho Dermatologics	300	-	-	300	371	-	371	(71)	-19%
Global Solta	253	(3)	-	250	194	-	194	56	29%
Total Ortho Dermatologics	553	(3)	-	550	565	-	565	(15)	-3%
Diversified Products									
Neurology & Other	674	-	-	674	715	(1)	714	(40)	-6%
Generics	415	-	-	415	459	-	459	(44)	-10%
Dentistry	73	-	-	73	101	-	101	(28)	-28%
Total Diversified Products	1,162	-	-	1,162	1,275	(1)	1,274	(112)	-9%
Total revenues	\$ 8,027	\$ 39	\$ (13)	\$ 8,053	\$ 8,601	\$ (20)	\$ 8,581	\$ (528)	-6%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Bausch + Lomb/Int'l Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M)

Three Months Ended	Calculation of Bausch & Lomb / International Organic Revenue							Change in Organic Revenue		
	Revenue as Reported	Changes in Exchange Rates ³	Acquisitions	Organic Revenue (Non-GAAP) ^{1,2}	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ^{1,2}	Amount	Pct.	
					Three Months Ended					
September 30, 2020	1,169	7	-	1,176	September 30, 2019	1,175	(3)	1,172	4	0%
June 30, 2020	883	27	-	910	June 30, 2019	1,208	(4)	1,204	(294)	-24%
March 31, 2020	1,114	17	-	1,131	March 31, 2019	1,118	(7)	1,111	20	2%
December 31, 2019	1,238	-	-	1,238	December 31, 2018	1,205	(6)	1,199	39	3%
September 30, 2019	1,175	15	-	1,190	September 30, 2018	1,147	(9)	1,138	52	5%
June 30, 2019	1,208	37	-	1,245	June 30, 2018	1,209	(12)	1,197	48	4%
March 31, 2019	1,118	58	-	1,176	March 31, 2018	1,103	(14)	1,089	87	8%
December 31, 2018	1,205	41	-	1,246	December 31, 2017	1,204	(22)	1,182	64	5%
September 30, 2018	1,147	29	-	1,176	September 30, 2017	1,234	(94)	1,140	36	3%
June 30, 2018	1,209	(25)	-	1,184	June 30, 2017	1,223	(84)	1,139	45	4%
March 31, 2018	1,103	(65)	-	1,038	March 31, 2017	1,134	(113)	1,021	17	2%
December 31, 2017	1,204	(31)	-	1,173	December 31, 2016	1,240	(116)	1,124	49	4%
September 30, 2017	1,234	15	-	1,249	September 30, 2016	1,226	(51)	1,175	74	6%
June 30, 2017	1,223	54	-	1,277	June 30, 2016	1,259	(51)	1,208	69	6%
March 31, 2017	1,134	41	-	1,175	March 31, 2016	1,131	(21)	1,110	65	6%
December 31, 2016	1,240	42	(13)	1,269	December 31, 2015	1,251	(11)	1,240	29	2%
September 30, 2016	1,226	7	(68)	1,165	September 30, 2015	1,182	(13)	1,169	(4)	0%
June 30, 2016	1,259	36	(76)	1,219	June 30, 2015	1,282	(11)	1,271	(52)	-4%
March 31, 2016	1,131	51	(83)	1,099	March 31, 2015	1,155	(11)	1,144	(45)	-4%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Salix Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M)

	Calculation of Salix Organic Revenue								Change in Organic Revenue	
	Revenue as Reported	Changes in Exchange Rates ³	Acquisitions	Organic Revenue (Non-GAAP) ^{1,2}	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ^{1,2}		Amount	Pct.
Three Months Ended					Three Months Ended					
September 30, 2020	496	-	-	496	September 30, 2019	551	-	551	(55)	-10%
June 30, 2020	404	-	-	404	June 30, 2019	509	-	509	(105)	-21%
March 31, 2020	477	-	(13)	464	March 31, 2019	445	-	445	19	4%
December 31, 2019	517	-	(18)	499	December 31, 2018	426	-	426	73	17%
September 30, 2019	551	-	(14)	537	September 30, 2018	460	(3)	457	80	18%
June 30, 2019	509	-	(17)	492	June 30, 2018	441	(3)	438	54	12%
March 31, 2019	445	-	(6)	439	March 31, 2018	422	(3)	419	20	5%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Global Solta Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M)

Calculation of Global Solta Organic Revenue									Change in Organic Revenue	
Three Months Ended	Revenue as Reported	Changes in Exchange Rates ³	Acquisitions	Organic Revenue (Non-GAAP) ^{1,2}	Three Months Ended	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ^{1,2}	Amount	Pct.
September 30, 2020	73	(1)	-	72	September 30, 2019	47	-	47	25	53%
June 30, 2020	42	-	-	42	June 30, 2019	45	-	45	(3)	-7%
March 31, 2020	51	1	-	52	March 31, 2019	38	-	38	14	37%
December 31, 2019	64	-	-	64	December 31, 2018	45	-	45	19	42%
September 30, 2019	47	-	-	47	September 30, 2018	29	-	29	18	62%
June 30, 2019	45	1	-	46	June 30, 2018	32	-	32	14	44%
March 31, 2019	38	1	-	39	March 31, 2018	29	-	29	10	34%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth^{1,2} (\$M)

	Calculation of Organic Revenue for the Three Months Ended						Change in Organic Revenue	
	December 31, 2020			December 31, 2019			Amount	Pct.
	Revenue as Reported	Changes in Exchange Rates ³	Organic Revenue (Non-GAAP) ^{1,2}	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ^{1,2}		
International Vision Care	149	(5)	144	149	-	149	(5)	-3%
Ocuvite® + PreserVision®	100	-	100	86	-	86	14	16%

	Calculation of Organic Revenue for the Twelve Months Ended						Change in Organic Revenue	
	December 31, 2020			December 31, 2019			Amount	Pct.
	Revenue as Reported	Changes in Exchange Rates ³	Organic Revenue (Non-GAAP) (b)	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) (b)		
International Vision Care	492	(1)	491	590	(1)	589	(98)	-17%
Ocuvite® + PreserVision®	333	3	336	313	-	313	23	7%

1. See Slide 2 and this Appendix for further non-GAAP information

2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.

3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Reported Net Cash Provided by Operating Activities to Adj. Cash Flows from Operations (non-GAAP)¹ (\$M)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2020	2019	2020	2019
GAAP Net cash provided by operating activities	\$ 394	\$ 234	\$ 1,111	\$ 1,501
Payments of legacy legal settlements, net	79	-	122	-
Payments of separation costs and separation-related costs	2	-	2	-
Adjusted cash flows from operations (non-GAAP)¹	\$ 475	\$ 234	\$ 1,235	\$ 1,501

TTM¹ Adjusted EBITDA² (\$M)

	Dec-20	Sep-20	Jun-20	Mar-20	Dec-19
Net loss attributable to Bausch Health Companies Inc.	\$ (560)	\$ (1,923)	\$ (2,043)	\$ (1,888)	\$ (1,788)
Interest expense, net	1,521	1,532	1,564	1,587	1,600
Benefit from income taxes	(375)	(86)	(109)	(6)	(54)
Depreciation and amortization	1,825	1,889	1,973	2,024	2,075
EBITDA	2,411	1,412	1,385	1,717	1,833
Adjustments:					
Asset impairments, including loss on assets held for sale	114	43	74	86	75
Restructuring and integration costs	11	15	18	15	31
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	48	36	37	50	25
Loss on extinguishment of debt	59	53	53	59	42
Share-based compensation	105	106	105	105	102
Separation and separation-related costs	32	5	-	-	-
Other adjustments:					
Litigation and other matters	422	1,516	1,521	1,422	1,401
IT infrastructure investment	21	25	26	27	24
Legal and other professional fees	39	41	38	36	35
Net gain on sale of assets	(1)	(22)	(23)	(22)	(31)
Acquired in-process research and development costs	32	52	41	41	41
Other	1	(1)	-	(3)	(7)
Adjusted EBITDA (non-GAAP)²	\$ 3,294	\$ 3,281	\$ 3,275	\$ 3,533	\$ 3,571

Non-GAAP Appendix

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. These measures do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to similar non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) is GAAP net income (loss) attributable to Bausch Health Companies Inc. (its most directly comparable GAAP financial measure) adjusted for interest expense, net, income taxes, depreciation and amortization and certain other items, as further described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company's underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Adjusted Cash Flows from Operations (non-GAAP)

Non-GAAP Appendix

Adjusted EBITDA (non-GAAP) is net income (loss) attributable to the Company (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and the following items:

Restructuring and integration costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. In addition, in connection with its acquisition of certain assets of Synergy Pharmaceuticals Inc. ("Synergy"), the Company has incurred certain severance and integration costs. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. With regard to the severance and integration costs associated with the acquisition of certain assets of Synergy, these costs are specific to the acquisition itself and provided no benefit to the ongoing operations of the Company. As a result, the Company does not believe that such costs (and their impact) are truly representative of its underlying business. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Asset Impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments, of intangible assets from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.

Goodwill Impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Adjusted Cash Flows from Operations (non-GAAP)

Non-GAAP Appendix

Share-based Compensation: The Company has excluded recorded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.

Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are impacted by the timing and size of its acquisitions. In addition, the Company has excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments is not consistent and is significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.

Loss on extinguishment of debt: The Company has excluded loss on extinguishment of debt as this represents a cost of refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such charges are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control.

Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities

taken to: (i) separate the eye-health business from the remainder of the Company and (ii) register the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to effectuating the separation of the eye-health business and include, but are not limited to; legal, audit and advisory fees, employee hiring, relocation and travel costs and costs associated with establishing a new board of directors and audit committee. Separation-related costs are incremental costs indirectly related to the separation of the eye-health business and include but are not limited to; IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP)
Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted
Gross Margin

Adjusted Selling, A&P/Adjusted
SG&A

Total Adjusted Operating Expense

Adjusted Net Income
(non-GAAP)

Adjusted Net Income (non-GAAP)
Adjustments

Organic Revenue / Organic Growth /
Organic Change

Constant Currency

Adjusted Cash Flows from
Operations (non-GAAP)

Non-GAAP Appendix

Other Non-GAAP Charges: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with recent legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net gain on sales of assets. The Company has also excluded expenses associated with in-process research and development, as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions.

Furthermore, as these amounts are associated with research and development acquired, the Company does not believe that they are a representation of the Company's research and development efforts during any given period. The Company has also excluded IT infrastructure investment, that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP)
Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted
Gross Margin

Adjusted Selling, A&P/Adjusted
SG&A

Total Adjusted Operating Expense

Adjusted Net Income
(non-GAAP)

Adjusted Net Income (non-GAAP)
Adjustments

Organic Revenue / Organic Growth /
Organic Change

Constant Currency

Adjusted Cash Flows from
Operations (non-GAAP)



Non-GAAP Appendix

Adjusted EBITA

Management uses this non-GAAP measure (the most directly comparable GAAP financial measure for which is Total GAAP Revenue less total operating expenses (GAAP)) to assess performance of its business units and operating and reportable segments, and the Company, in total, without the impact of foreign currency exchange fluctuations, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs. In addition, it excludes certain acquisition related contingent consideration, acquired in-process research and development, asset impairments, restructuring, integration and acquisition-related costs, amortization of finite-lived intangible assets, other non-GAAP charges for wind down operating costs, and legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices. The Company believes the exclusion of such amounts provides supplemental information to management and the users of the financial statements to assist in the understanding of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.

EBITA/EBITA Margin

EBITA represents earnings before interest, taxes and amortizations.

Adjusted Gross Profit/Adjusted Gross Margin

Management uses these non-GAAP measures (the most directly comparable GAAP financial measures for which are gross profit and gross margin) to assess performance of its business units and operating and

reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations, and fair value adjustments to inventory in connection with business combinations. Such measures are useful to investors as it provides a supplemental period-to-period comparison. Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.

Adjusted Selling, A&P/Adjusted G&A/Adjusted SG&A

Management uses these non-GAAP measures (the most directly comparable GAAP financial measure for which is selling, general and administrative) as a supplemental measure for period-to-period comparison. Adjusted Selling, General and Administrative excludes, as applicable, separation-related costs, certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices. See the discussion under "Other Non-GAAP charges" above. Please also see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Total Adjusted Operating Expense

Management uses this non-GAAP measure (the most directly comparable GAAP financial measure for which is total operating expenses (GAAP)) as a supplemental measure for period-to-period comparison. This non-GAAP measure allows investors to supplement the evaluation of operational efficiencies of the underlying business without the variability of items that the Company believes are not normal course of business. Please see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the period presented

Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Adjusted Cash Flows from Operations (non-GAAP)

Non-GAAP Appendix

Adjusted Net Income (non-GAAP)

Historically, management has used Adjusted net income (non-GAAP) (the most directly comparable GAAP financial measure for which is GAAP Net Income (Loss)) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described below) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. It is management's belief that this measure is also useful to investors as such measure allowed investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, it is the Company's belief that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance and the valuation of the Company. It is also noted that, in recent periods, our GAAP net income (loss) was significantly lower than our Adjusted net income (non-GAAP). Commencing in 2017, management of the Company identified and began using certain new primary financial performance measures to assess the Company's financial performance. However, management still believes that Adjusted net income (non-GAAP) may be useful to investors in their assessment of the Company and its performance.

Adjusted Net Income (non-GAAP) Adjustments

Adjusted net income (non-GAAP) is net income (loss) attributable to Bausch Health Companies Inc. (its most directly comparable GAAP financial measure) adjusted for restructuring and integration costs, acquired in-process research and development costs, loss on extinguishment of debt, asset impairments, acquisition-related adjustments, excluding amortization, separation and separation-related

costs and other non-GAAP charges), as these adjustments are described above, and amortization of intangible assets as described below:

Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

Please see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Adjusted Tax Rate

Adjusted Tax Rate includes the tax impact of the various non-GAAP adjustments used in calculating our non-GAAP measures. Due to the differences in the tax treatment of items excluded from non-GAAP earnings, our adjusted tax rate may differ from our GAAP tax rate and from our actual tax liabilities.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Adjusted Cash Flows from Operations (non-GAAP)

Non-GAAP Appendix

Organic Revenue, Organic Growth, Organic Revenue Decline and Organic Change

Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations (if applicable). Organic growth/change is change in GAAP Revenue (its most directly comparable GAAP financial measure) adjusted for certain items, as further described below, of businesses that have been owned for one or more years. Organic revenue is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue and organic growth/change to assess performance of its business units and operating and reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.

Organic growth/organic change reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/ or discontinued. These adjustments are determined as follows:

- *Foreign currency exchange rates:* Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

- *Acquisitions, divestitures and discontinuations:* In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue (non-GAAP) growth/change excludes from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue (non-GAAP) growth/change excludes from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Please also see the reconciliation in this Appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for foreign currency effects.

Constant currency impact is determined by comparing 2020 reported amounts adjusted to exclude currency impact, calculated using 2019 monthly average exchange rates, to the actual 2019 reported amounts.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Adjusted Cash Flows from Operations (non-GAAP)

Non-GAAP Appendix

Adjusted Cash Flows from Operations (non-GAAP)

Adjusted cash flows from operations (non-GAAP) is Cash provided by operating activities (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds and (ii) payments for separation costs and separation-related costs. As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Management believes that Adjusted cash flows from operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses Adjusted net cash provided by operating activities (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted net cash provided by operating activities (non-GAAP) is a useful measure to evaluate current performance amounts.



Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP)
Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross
Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income
(non-GAAP)

Adjusted Net Income (non-GAAP)
Adjustments

Organic Revenue / Organic Growth /
Organic Change

Constant Currency

Adjusted Cash Flows from Operations
(non-GAAP)